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“Please be on time! Early = on time, on time = late, late = really late.” 







Acute myocardial infarction (AMI) is a main cause of death. Despite vast improvements in 
management and treatment strategies over the past decades, morbidity and mortality after an 
AMI remains high. For patients with AMI and ST-segment elevations (STEMI), urgent 
management has been shown to be associated with reductions in both morbidity and 
mortality. Various pre-hospital management strategies have been implemented, during which 
STEMI patients can be referred directly to the catheterization laboratory instead of first being 
assessed in the emergency department. Valuable minutes can thus be saved. However, it is 
important that the diagnosis is correct which can be more challenging in a setting where the 
referring cardiologist is not at the same location as the patient and the clinical setting 
therefore needs to be reported by the paramedic staff. Studies on the accuracy of pre-hospital 
STEMI diagnoses are limited. In order to expedite management for STEMI patients, 
international guidelines have included benchmark time targets. Little is known regarding 
gender differences in the achievement of these time targets, and the feasibility of obtaining a 
pre-hospital ECG within ten minutes of ambulance arrival has been questioned.  
For patients who survive an AMI, there is a risk of transient or permanent damage to the left 
ventricle. Such damage can be quantified by echocardiography. It is shown that patients with 
a reduced left ventricular ejection fraction (LVEF) have a higher risk of sudden cardiac death 
than patients with normal LVEF. For patients with reduced LVEF despite optimal medical 
treatment, an implantable cardioverter defibrillator (ICD) can reduce mortality. This benefit is 
not seen until after several months have passed since the AMI. This is further complicated by 
the fact that the risk of death is highest in the early days, weeks and months after an AMI. 
Therefore, finding predictors in the early phase after an AMI, preferably while the patient is 
still admitted to the ward, would likely be beneficial in the selection of patients for ICD 
treatment.  
Aims 
The overall aim of this thesis was to find easily obtainable measurements by ECG and 
echocardiography that could improve the prognosis for patients with acute myocardial 
infarction. More specifically, the aim was to study the rate of false-positive STEMI diagnoses 
based on pre-hospital ECGs (study I), study gender differences in time intervals and 
adherence to guideline set time targets (study II), study the predictive value of low-dose 
dobutamine stress echocardiography on the improvement of LVEF (study III) and investigate 




In study I all patients for whom a pre-hospital ECG had been transmitted to the investigating 
hospital during 2013 were included. In study II, patients with a STEMI diagnosis and a pre-
hospital ECG between December 2010 and July 2015 were included. Information on whether 
a pre-hospital STEMI diagnosis had been set or not was collected from medical charts and 
the final diagnosis of STEMI was found in the national quality registry SWEDEHEART. For 
both study I and study II, information on time intervals were collected from ambulance 
charts, medical charts, a database collecting information on pre-hospital ECGs, and 
SWEDEHEART.  
In studies III and IV, adult patients with an at least moderately reduced left ventricular 
function (defined as LVEF ≤ 40%) with a life expectancy of more than one year and who 
were admitted for AMI were invited and followed by clinical visits and echocardiographic 
examinations. In study III, a low-dose dobutamine stress echocardiogram was performed 
within one week of the AMI and in study IV, the discharge ECG was reviewed. 
Results  
In study I, 16% (95% CI 10 – 23) out of 115 patients with a suspected STEMI based on pre-
hospital ECGs were discharged with alternative diagnoses. Measured as the time from 
ambulance arrival at the patient’s location, the time target of reperfusion therapy within 90 
minutes was achieved for almost all patients (98%), but the achievement of a pre-hospital 
ECG within ten minutes was only met for 16% of the cohort. The delay time to pre-hospital 
ECG was significantly longer for women than for men, 20 vs. 13 minutes (p < 0.001). 
In study II, 539 patients with STEMI and a pre-hospital ECG were included. A pre-hospital 
ECG was obtained within ten minutes for 22% of the cohort, and the target was more likely 
to be achieved for men than for women (29% vs. 14%, p = 0.001). Among all patients, 88% 
reached the target of reperfusion therapy within 90 minutes and there was no difference 
between men and women. Women had a significantly longer delay time between symptom 
onset and emergency call than men (median 61 vs. 45 minutes, p = 0.031).  
In study III, among 96 patients with an at least moderately reduced LVEF after an AMI, 60% 
had an LVEF ≥ 35% after three months. Patients with an LVEF ≤ 35% after three months had 
a significantly lower left ventricular function at both resting and stress echocardiography, 
measured as LVEF, mitral annular plane systolic excursion (MAPSE) and peak systolic 
velocity (PSV). Baseline LVEF was a good predictor of recovery with a C-statistic of 85% 
(95% CI 74 – 94). None of the other variables, including the stress echocardiography 
variables, were better discriminators. 
In study IV, 87 patients with LVEF ≤ 40% after an AMI were included. Patients who had a 
pathologic R-wave progression on the discharge ECG were four times more likely to receive 
 
 
an ICD than those with normal R-wave progression (HR 4.0, 95% CI 1.1-14.3, p = 0.033). 
None of the patients without a pathologic R-wave progression, pathologic Q-waves, or intra-
ventricular conduction abnormalities, received an ICD or suffered from malignant 
arrhythmias during the follow-up period.  
Conclusions 
The rate of false-positive catheterization laboratory activations based on pre-hospital STEMI 
diagnoses is well in comparison to rates reported based on in-hospital triage. Still, there are 
gender differences favoring men in regards of delay time from symptom onset to emergency 
call and ambulance arrival to pre-hospital ECG. The target of obtaining a pre-hospital ECG 
within ten minutes is met for only around one fifth of the patients, and improvements 
regarding this are warranted. For patients with heart failure after an AMI, baseline LVEF is a 
strong predictor of improved recovery while simple measurements of LVEF, MAPSE and 
PSV during low-dose dobutamine stress echocardiography did not add prognostic 
information. Patients with a pathologic R-wave progression have a significantly higher risk of 
receiving an ICD, and patients without pathologic R-wave progression, or Q-waves, or intra-
ventricular conduction abnormalities are unlikely to receive an ICD and could be seen as a 
low-risk population.  
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For patients with certain types of acute myocardial infarction (AMI), rapid and correct 
management and treatment can reduce the risk of death and heart failure. Despite efforts, the 
risk of ischemic heart failure after an AMI remains significant. If heart failure persists despite 
optimal medical treatment, an implantable cardioverter defibrillator (ICD) can reduce 
mortality. Earlier and more precise identification of patients suitable for ICD treatment is also 
likely to reduce mortality. In this thesis, these aspects will be discussed and explored further. 
1.2 EPIDEMIOLOGICAL ASPECTS 
Cardiovascular disease (CVD), and especially ischemic heart disease (IHD), is the leading 
cause of death, both globally and in Sweden, and accounts for approximately 15% of all 
deaths in the world (table 1) (1-6). During the past decades, age-standardized death rates due 
to CVD have declined, especially in high-income countries (4, 5). The cause of this decline is 
likely to be multifactorial, where improved primary and secondary prevention as well as 
improved treatments are key factors (7, 8). Nevertheless, every year some 0.3% of the 
population will suffer from an AMI and among them up to one in four will die from it.  
 
Table 1:  Mortality and incidence data on ischemic heart disease and acute myocardial infarction.  
Region Year Total number 
of deaths by 
IHD or AMI 
Percentage of 
all deaths 
caused by IHD 
or AMI 
AMI / 100,000 
inhabitants 
Mortality < 
28 - 30 days 
Ref. 
Global 2019 8.9 million 16%   (1) 
Europe < 2016 1.8 million  20% 172 - 31721 5 – 15% (4) 
USA 2013 -
2017 
110,000 14%  203 14 – 16% (6, 9-11) 
Sweden 2019 5,200 6% 311 11 – 25% (12, 13) 
1 Lowest number from Andorra, highest number from Belarus 





1.3 DEFINITIONS  
1.3.1 Acute Myocardial Infarction 
An AMI is defined as the situation when there is clinical evidence of acute myocardial 
ischemia and acute myocardial injury due to a mismatch in the supply and demand of oxygen 
(figure 1) (14).  
Figure 1: Definition of the term acute myocardial infarction, based on the fourth universal definition of 
myocardial infarction (14). cTn = cardiac troponin, ECG = electrocardiogram 
Based on the underlying pathophysiology or clinical situation, the diagnosis of myocardial 
infarction can be further divided into subgroups (14): 
Type 1: A ruptured or erosive plaque causes an occlusive or non-occlusive thrombus in a 
coronary vessel, leading to a myocardial infarction.  
Type 2: An imbalance between oxygen supply and demand to the cardiac muscle, not caused 
by a ruptured plaque or thrombus. Other conditions, such as atherosclerosis, coronary spasm, 
or coronary dissection may, but do not have to, be present.  
Type 3: Patients with symptoms and ECG-findings congruent with AMI who die before 
blood samples are obtained, or before a rise and/or fall in cardiac troponin (cTn) can be 
quantified. 
Type 4a-c: Post-procedure myocardial infarction after percutaneous coronary intervention 
(PCI). 
Type 5: Post-procedure myocardial infarction after coronary artery bypass graft (CABG) 
surgery. 
In the clinical setting, ECG findings are of main importance to distinguish patients with ST-
segment Elevation Myocardial Infarction (STEMI) from patients without such elevations, 
non-STEMI, as the importance of urgent reperfusion differs between the groups (15, 16).  
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1.3.2 Myocardial injury 
Myocardial injury is defined as when cTn levels found in blood samples are higher than the 
99th percentile upper reference levels (14). When there is a rise and/or fall in cTn, the 
myocardial injury is considered acute. Apart from AMI, there are numerous other conditions 
that can cause myocardial injury, both cardiac (e.g. myocarditis, heart failure) and non-
cardiac (e.g. stroke, sepsis, kidney failure) (14, 17). 
1.3.3 Coronary Artery Disease 
Coronary Artery Disease (CAD) involves the build-up of atherosclerosis in coronary vessels. 
The disease entity itself is usually further divided into acute coronary syndrome (ACS), 
including myocardial infarction and unstable angina pectoris, or chronic coronary syndrome 
(18).  
1.4 RISK FACTORS 
1.4.1 The Framingham Heart Study and the INTERHEART study 
Much of our knowledge today regarding risk factors for CVD comes from the Framingham 
Heart Study. Although accounting for about 50% of all deaths in the United States in the 
1940s, little was understood at the time regarding risk factors (19). Between the years 1948 
and 1952, the first original cohort, consisting of 5,209 (55% female) residents of 
Framingham, Massachusetts, without known CVD, was recruited (19, 20). Participants were 
invited for medical interviews and examinations, and then followed up biannually. Over the 
seven decades that have passed since the first inclusion, five additional cohorts (including 
offspring, spouses and general population reflecting ethnic diversity) have been recruited and 
more than 3,500 scientific papers have been published (20). Many of the findings from the 
Framingham cohort have also been supported by other studies. The INTERHEART study 
was an international case-control study (15,152 cases, 14,820 controls), aiming to investigate 
risk factors for myocardial infarction on a global perspective and also the population 
attributable risk (PAR) for each risk factor (21). The PAR can be seen as the fraction of a 
particular outcome that is attributed to a certain risk factor (22). Combined, nine risk factors 
accounted for over 90% of the PAR. Some of the main findings from the Framingham and 
INTERHEART studies regarding risk factors for CVD and AMI are summarized in table 2. 
Main risk factors include: hypertension, diabetes, hyperlipidemia, obesity, smoking, age, and 
physical inactivity (19, 21, 23). 
1.4.2 Risk scores 
Several tools have been developed to evaluate the risk of CVD. The European Society of 
Cardiology (ESC) recommends the use of SCORE (the Systematic COronary Risk 
Evaluation), which estimates the ten-year risk of fatal CVD (24, 25). The SCORE charts are 
based on twelve European cohort studies containing 2.7 million patient years of follow-up 
and 5,652 deaths due to coronary heart disease (25). Other risk scores include the 




Table 2: Two major studies determining risk factors for coronary vascular disease (Framingham Heart 
Study) and acute myocardial infarction (INTERHEART).  
 Framingham Heart Study (23) INTERHEART (21) 
Study design Cohort Case-Control 
Number of cases 610 (37% women) 15,152 (38% women) 
Number of 
participants 5,345 (53% women) 29,972 (32% women) 
Outcome Coronary Vascular Disease Acute Myocardial Infarction 
Inclusion site Framingham, Massachusetts, USA 52 countries, all inhabited continents 
Publication year 1998 2004 
Risk reported Relative Risk (95% CI) adjusted for 
all other variables in table 
OR (99% CI) adjusted for age, sex and 
geographic region 
 Men Women Men Women 
Age 1.1 (1.0 – 1.1) 1.04 (1.0 – 1.1)   
Current smoking 1.7 (1.4 – 2.1) 1.5 (1.1 – 1.9) 3.1 (2.8 – 3.3) 2.9 (2.4 – 3.5) 
Hypertension 1 1.7 (1.3 – 2.2) 1.7 (1.2 – 2.5) 2.3 (2.1 – 2.5) 3.0 (2.6 – 3.4) 
Diabetes 1.5 (1.1 – 2.1) 1.8 (1.2 -2.7) 2.7 (2.4 – 3.0) 4.3 (3.5 – 5.2) 
Abdominal obesity   2.4 (2.0 – 2.5) 2.3 (1.9 – 2.7) 
Physical activity   0.8 (0.7 – 0.9) 0.5 (0.4 – 0.6) 
Psychosocial stress   2.6 (2.1 – 3.1) 2.5 (2.4 - 5.0)  
Alcohol   0.9 (0.8 – 1.0) 0.4 (0.3 – 0.5) 
LDL (> 160 mg/dL) 1.7 (1.4 – 2.2) 1.7 (1.2 -2.4)   
ApoB/ApoA1   3.8 (3.2 – 4.4) 4.4 (3.4 – 5.7) 
1 Framingham defined as ”hypertension I” as 140-159 mmHg in systolic blood pressure or 90-99 
mmHg in diastolic blood pressure, compared with normotensives < 130/85 mmHg. INTERHEART 
defined hypertension by self-report. 




1.5 NON-INVASIVE INVESTIGATIONS 
1.5.1 Clinical presentation 
Symptoms consistent with myocardial ischemia are of main importance in establishing the 
diagnosis myocardial infarction (14). Chest pain is the cardinal symptom and around 80% of 
patients with AMI present with chest pain (26). Other common symptoms include diaphoresis 
(≈ 45%), nausea (≈ 40%), and pain radiating to the left arm (≈ 30%) (26). In the TRAPID-
AMI (high sensitive cardiac Troponin T assay for RAPID rule-out of Acute Myocardial 
Infarction) study, over 1,282 patients seeking emergency care for chest pain within six hours 
of symptom onset were included and interviewed by research staff (patients with ST-segment 
elevations were excluded) (27). Among included patients, 17% were diagnosed with AMI. 
Four independent variables were associated with AMI; pain radiating to the left or right arm 
or shoulder respectively, chest pressure, or symptoms worsened by physical activity (27). 
There also seem to be differences between male and female patients. One meta-analysis (n = 
951,474) found that women with AMI were less likely to report chest pain than men (OR 
0.63, 95% CI 0.59 – 0.68) (28), although other studies have found no such difference (26). 
However, women seem more likely to present with other symptoms such as nausea or neck 
pain (26, 28). 
Although chest pain is a common complaint in AMI patients, most patients seeking 
emergency care for chest pain do not have acute coronary syndrome (27), and it is thus 
important to have non-objective tools when assessing these patients.  
1.5.2 Cardiac troponin 
Cardiac troponin is a protein complex involved in the interaction between actin and myosin in 
heart muscle cells (14). When such cells are injured, cTn is released into the blood stream and 
can be detected and quantified in blood samples. For the detection of myocardial injury, high-
sensitivity assays are recommended, as these assays have a higher diagnostic accuracy in the 
early detection of AMI (29). It is important to stress that cTn should be interpreted in 
combination with the clinical presentation and with other findings as all patients with 
elevated cTn levels do not have AMI.  
1.5.3 The ECG 
1.5.3.1 A brief history 
The knowledge that electrical currents can be detected from skeletal muscle dates back to the 
late 1700s, and the first human recording of cardiac electrical activity was published by Dr. 
Waller in 1882 (30). Inspired by Dr. Waller, Dr. Einthoven developed the first three-lead 
electrocardiogram in 1901 for which he was later awarded the Nobel Prize in Physiology or 
Medicine. Further milestones in the development of modern ECG machines were the central 
terminal (Dr. Wilson, 1934-38) and the augmented unipolar leads (Dr. Goldberger, 1942). In 
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1954 the American Heart Association published their recommendations on the 12-lead ECG 
as we know it today (30). 
1.5.3.2 The normal ECG 
The standard 12-lead ECG records differences in electrical potential between defined sites on 
the body surface (figures 2A and B) (31). More specifically, it reflects the progression of the 
trans-membrane difference in action potential of the heart muscle cells over the cardiac cycle 
and the ECG thus describes the electrical events of cardiac depolarization and repolarization. 
The variations of potential are caused mainly by the movement of K+, Na+ and Ca++ across 
the cell membrane (32). This cycle of inward and outward movement of electrolytes is in part 
dependent on adenosine triphosphate. The signals recorded from the electrodes are then 
filtered to reduce disturbances, e.g. from respiration, muscle artifacts, and movement. The 
result is a graphical presentation, consisting of a series of complexes depicting the electrical 
activity in the heart viewed from twelve different sites (figure 2C). The different positive and 
negative deflections are noted with the letters PQRST (figure 2D). A wave of depolarization 
moving toward, or a wave of repolarization moving away from the positive electrode will 
generate a positive wave on the ECG, and the magnitude of the wave depends on the mass of 
cardiac tissue undergoing depolarization or repolarization (32).  
Figure 2: Illustrations of A) Bipolar leads of Einthoven and unipolar leads of Goldberger, acquired by 






1.5.3.3  Interpretation of the ECG 
In the clinical setting, the ECG is possibly the most commonly used diagnostic instrument as 
it is easy to acquire, non-invasive, and provides a wide range of information. In order to 
facilitate and standardize interpretations and readings of ECGs, the American Heart 
Association, The American College of Cardiology Foundation and the Heart Rhythm 
Foundation published a six-part series of recommendations (31, 33-37). Interpretation of an 
ECG is an integral part of cardiologist training, but experienced cardiologists cannot read all 
ECGs.  
In many cases, a computerized interpretation (CIE) is provided, and the ECG is then over-
read by other professionals such as nurses, emergency medical services, or specialist 
physicians in other areas of medicine. The role of CIE is appealing as it facilitates the 
readings for the physician, e.g. by providing measurements of basic parameters such as heart 
rate, but CIE is not always accurate. Also, conducting and comparing studies on CIE usually 
involve the use expert readers such as experienced cardiologists, who sometimes might 
disagree, as gold standard. In the setting of STEMI, three different CIE algorithms were 
evaluated for the identification of a culprit artery. The sensitivities ranged from 62 - 69% and 
specificities from 89 - 95% (38). The general recommendations remain that all CIE are over-
read by an experienced ECG reader (39). 
1.5.3.4 ECG findings in or after AMI 
Acute myocardial ischemia can cause different types of ECG disturbances. When hypoxia 
occurs to the heart muscle cell, adenosine triphosphate is reduced and extracellular potassium 
is increased. This causes disturbances in the movement of ions across the cell membrane and 
can lead to a variety of changes, such as changes in heart rhythm, conduction blocks and also 
changes in the morphology of the ST-segment. The definitions of some of the most common 




Table 3: Definitions and pathophysiology of ECG findings during or after a myocardial infarction.  




New, or presumed new, ST-
elevations measured at the J-point 
(the onset of the ST-segment) of at 
least 1 mm in two contiguous leads, 
with the exception of V2-V3 where ≥ 
2.5 mm is required in men < 40 years, 
≥ 2 mm in men ≥ 40 years and ≥ 1.5 
mm in women, in the absence of 
signs of left ventricular hypertrophy 
or left ventricular bundle branch 
block. 
Generally indicative of a transmural 
ischemia. The damaged region causes 
an area of depolarization. Vectors 
occur moving away from the 
overlying electrode between the 
damaged and healthy areas when the 
healthy areas are repolarized, causing 






New, or presumed new, horizontal or 
downward-sloping ST-depressions of 
≥ 0.5 mm in two contiguous leads. 
Generally indicative of a 
subendocardial ischemia. When the 
ventricle is fully repolarized, vectors 
between the damaged and healthy 
areas occur, causing an upward shift 






New inverted T-waves of ≥ 1 mm in 
two contiguous leads where the R-
wave is prominent or the R/S-ratio > 
1. 
In the setting of a subendocardial 
infarction, the wave of repolarization 
may change from the normal 
subendocardial to subepicardial 
direction and instead may become 
subepicardial to subendocardial, thus 





Any Q-waves in V2-V3 > 20 ms or 
QS complex in V2-V3, or Q-waves ≥ 
30 ms or QS-complex in leads aVL, 
I, II, aVF or V4-V6 in any two leads 
of a contiguous lead grouping. 
In early depolarization, the net 
electrical forces move away from the 
overlying electrode. Correlated to 






Poor R-wave progression: R in V3 ≤ 
3 mm. Reversed R-wave progression: 
R-wave in V2 < V1, V3 < V2, V4 < 
V3 or V4 ≤ 3 mm. 







1.5.3.5 The significance of Q-waves and pathologic R-wave progression 
Various studies have demonstrated that for patients with STEMI, the presence of Q-waves on 
the presenting ECG is associated with a poor prognosis (42, 43). One systematic review (n = 
20,842) found that for STEMI-patients presenting with Q-waves, the risk of death within 30 
days was about twice as high compared to patients without Q-waves (RR 2.2, 95% CI 1.3 – 
3.6) (42). The presence of Q-waves is also associated with infarct size (44, 45). There is a 
possibility that Q-waves can regress after reperfusion and over time. One study among 761 
STEMI-patients found a reduction the number of Q-waves between post-PCI and discharge 
for 22% of the patients (46). In the same study, patients with persistent Q-waves had an 
almost five-fold increased risk of heart failure or death within one year compared to patients 
without Q-waves.  
Pathologic R-wave progression signifies a decreased magnitude of the R-wave in the 
precordial leads, and has been associated with anterior myocardial infarctions. It has also 
been associated with heart failure, and patients with prior anterior AMI who have a 
pathologic R-wave progression have a lower left ventricular ejection fraction (LVEF) on 
echocardiography than patients with normal R-wave progression (average LVEF 46% vs. 
55%, p < 0.01) (47). For patients without a known myocardial infarction, the use of 
pathologic R-waves for the identification of patients with a prior silent myocardial infarction 
has, however, been questioned. One study showed that only around 30% of 122 patients 
referred to pharmacological stress tests and who had a pathologic R-wave progression had 
evidence of anterior ischemia, which was not significantly different from patients with 
normal R-wave progressions (48). 
1.5.3.6 The role of the ECG in predicting sudden cardiac death  
The use of pathologic findings on resting ECGs in the prediction of sudden cardiac death 
(SCD) was explored in the community-based Oregon Sudden Unexpected Death Study. The 
study was a multi-center case-control study including 522 cases with out-of-hospital cardiac 
arrests (including survivors of cardiac arrest) and 736 controls. An ECG score consisting of 
eight ECG variables (heart rate, QRS-duration, corrected QT-time, T-peak-Tend duration, 
QRS-T angle > 90%, delayed QRS transition zone, left ventricular hypertrophy and R-wave 
peak time) was analyzed and the authors concluded that, after adjusting for clinical factors 
and LVEF, a higher ECG score was associated with a higher risk of cardiac arrest. For 
patients with an ECG score > 4, the OR was 21.2 (95% CI 9.4 – 47.7, p < 0.001) (49).  
More advanced three-dimensional ECG markers on global electric heterogeneity based on 
standard 12-lead ECGs but measured by computer software have been found to be 
independently associated with the risk of SCD. Two large prospective American cohorts; 
ARIC (the Atherosclerosis Risk in Communities, n = 15,792) and CHS (the Cardiovascular 
Health Study, n = 5,888) were merged. Markers of global electric heterogeneity were 
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independently associated with an increased risk of SCD in the general population and 
inclusion of such parameters to clinical risk scores improved risk prediction (50). 
In patients with prior myocardial infarction, the use of the Selvester QRS-scores (based on 
amplitudes, durations and ratios of the Q, R, and S waves in ten out of twelve ECG leads) has 
been studied in the SCD-HeFT (Sudden Cardiac Death – Heart Failure Trial) and the MADIT 
II (Multicenter Automatic Defibrillator Implantation Trial) (51, 52). In the SCD-HeFT, 
patients with a normal QRS-score had a significantly lower risk of experiencing malignant 
ventricular arrhythmias, HR 0.52 (95% CI 0.31 – 0.88), whereas the results in the MADIT II 
were non-significant. The authors speculate that the lower LVEF cutoff value for inclusion in 
MADIT II could contribute to this finding. 
Other ECG-based measurements, including bundle branch blocks and QRS-duration on 
resting ECG, electrophysiological studies, signal averaged ECG, T-wave alternans and heart 
rate variability on Holter ECG, have also been explored for the prediction of SCD in patients 
with myocardial infarction (53).  
1.5.4 Echocardiography 
1.5.4.1 A brief history 
The discovery of the piezoelectric effect (the effect that kinetic or mechanical energy can be 
converted to electrical energy) is attributed to the Curie brothers during the 1880s (54). 
Clinical echocardiography started in 1953 in Lund, Sweden, by Edler and Hertz, who then, by 
the use of an ultrasound machine connected to a camera, recorded the first non-invasive 
picture of a moving structure in the heart (55). Over the decades that have since passed, the 
technique has been vastly improved. Some of the milestones are the development of 2D 
echocardiography in the 1960s and Doppler echocardiography in the 1970s (54). Digital 
storing of information, transesophageal echocardiography, contrast enhancing agents and 3D 
echocardiography have further expanded the clinical use of echocardiography. 
1.5.4.2 Ejection fraction 
Left ventricular ejection fraction is defined as the difference between the left ventricular end-
diastolic volume and end-systolic volume, divided by the end-diastolic volume (56). The 
recommended methods for the echocardiographic measurement of LVEF are either 3D 
echocardiography or the Simpson biplane method of discs using 2D. LVEF can be seen as a 
method to measure left ventricular global function. Echocardiographic reference values for 
LVEF are 54 - 74% for women and 52 - 72% for men (56).  
The ESC guidelines on heart failure define heart failure as a clinical diagnosis based on 
symptoms (e.g. shortness of breath, ankle swelling) and signs (e.g. pulmonary crackles and 
edema) caused by a structural or functional cardiac abnormality that leads to decreased 
cardiac output and/or increased filling pressures at rest or during exercise (57). The second 
criteria for the diagnosis is based on LVEF; where LVEF < 40% is referred to as heart failure 
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with reduced LVEF and LVEF > 50% referred to as heart failure with preserved LVEF. For 
patients with heart failure and LVEF 40-49% the term heart failure with mid-range LVEF is 
used.  
For patients with myocardial infarction, many studies have found a clear association between 
low LVEF and a poor prognosis (58, 59). Also, for patients with STEMI, shorter delay times 
between presentation and reperfusion therapy is associated with higher LVEF at follow-up 
(60, 61). 
1.5.4.3 Stunning, hibernation, and stress echocardiography 
Echocardiography is recommended during hospital stay for patients with AMI (15, 16, 62). 
Left and right ventricular global and regional functions are assessed and mechanical 
complications and thrombus formation can be ruled out. In the case of suspected, but not 
confirmed, acute coronary syndrome alternative diagnoses such as pericardial effusion or 
aortic dissection may be identified.  
The reaction of the left ventricle to the ischemic situation will in large depend on the extent 
and duration of the ischemia. If the ischemia is severe and prolonged, necrosis of the affected 
area of the left ventricle will occur and the necrotic myocardium will not recover. If however 
the duration of the ischemic episode is transient, the affected segments of the ventricle that 
initially show impaired contractile function may recover over time. This is referred to as 
myocardial stunning (63, 64). If there are repeated episodes of stunning, or a more chronic 
situation with reduced perfusion, metabolic adaptations will occur in the heart muscle cells. 
Although still viable, these cells may not contract during rest but can still recover after 
reperfusion. This phenomenon is referred to as hibernation (63, 64). In the clinical setting it 
can be of importance to differentiate hibernating or stunned regions from necrotic ones. 
Stress echocardiography can be used to detect myocardial viability. Using a low dose of 
dobutamine as a continuous infusion, akinetic or hypokinetic segments may improve in 
contraction implying viability and that a contractile reserve exists (63, 64).  
1.6 EARLY REVASCULARIZATION FOR PATIENTS WITH STEMI 
Early reperfusion treatment for patients with STEMI is associated with decreased mortality. 
A large American cohort study, based on registry data on more than 29,000 STEMI patients 
treated by PCI within six hours of presentation between 1999 and 2002, found that a door-to-
balloon time longer than 90 minutes was associated with an increased risk of in-hospital 
death, HR 1.4 (95% CI 1.2 – 1.6) (65). These findings were congruent with what was 
reported from the GUSTO-IIb study (Global Use of Strategies to Open Occluded Arteries in 
Acute Coronary Syndromes), where the risk of death within 30 days increased 1.6 times 
(95% CI 1.1 – 2.3, p = 0.008) per 15 minutes delay time measured as the time from 
enrollment in the study to balloon inflation (66). Similarly, a Swedish registry-based cohort 
study investigated the association between the time from first medical contact (FMC) to PCI 
versus death within one year among more than 13,000 patients treated between 2003 and 
2009. In this study, a hazard ratio for all cause mortality of 1.26 (95% CI 1.03-1.55) was 
 
12 
found comparing delay times 61-90 minutes to < 30 minutes, and higher hazard ratios with 
even longer delay times (67).  
1.7 TIME MANAGEMENT AND TIME COMPONENTS 
1.7.1 Time targets and components 
Due to the benefits of early or immediate reperfusion therapy for patients with STEMI, 
current international guidelines advocate rapid identification and primary PCI for these 
patients (15). The time target for a diagnosis of STEMI, defined as when the ECG is 
interpreted and ST-elevations or equivalents are confirmed, is set within ten minutes from 
ambulance arrival. For patients who arrive by emergency medical services (EMS) or for self-
presenters to non-PCI-capable hospitals, the goal is then primary PCI within 90 minutes, if 
such therapy is available (15). For self-presenters at PCI-capable hospitals, the goal is 
primary PCI within 60 minutes from STEMI diagnosis. The total ischemic time can thus be 
divided into several time components for benchmarking compared to international guidelines 
and in order to identify possible areas of improvement (figure 3). 
 
Figure 3: An overview of delay times for patients with STEMI arriving by EMS, including both pre-
hospital and in-hospital delay times. Black boxes denote target delay times in minutes according to the 







patient arrives at hospital 
arterial puncture 
wire crossing 
patient delay system delay 
1 2 3 4 
1)  EMS delay = time from emergency call to the EMS arrives 
2)  ECG delay = time from EMS arrival until a pre-hospital ECG is 
transmitted 
3)  Transportation delay = time from pre-hospital ECG to the arrival at the 
hospital 
4)  Hospital delay = time from arrival at the hospital to arterial puncture or 
wire crossing 




1.7.2 Pre-hospital alerts 
Various alert systems have been developed in order to reduce ischemic time for patients with 
STEMI, and the guidelines recommend implementation of efficient networks between 
hospitals and EMS services (15, 68). For patients with STEMI, it has been shown that 
contacting EMS yields the shortest total ischemic times, compared to self-presentation in the 
emergency department or first contacting primary care (69). The use of pre-hospital ECGs, 
with the possibility of bypassing the emergency department and referring the patient directly 
from the ambulance to the catheterization laboratory (CL), has been shown to be associated 
with shorter delay times (70-73). Through such systems, EMS personnel acquire a pre-
hospital ECG and the ECG is then either transferred wirelessly to a receiving hospital or 
interpreted by paramedics or EMS physicians on site. If the symptoms and the ECG are 
consistent with STEMI, the CL can immediately be activated and necessary preparations can 
be done during transport. In many systems, the patient does not have to stop in the emergency 
department but can be taken directly to the CL.  
There is a trend towards reductions in delay times for STEMI patients. The national quality 
registry SWEDEHEART (Swedish Web-system for Enhancement and Development of 
Evidence-based care in Heart disease Evaluated According to Recommended Treatment) 
reported a reduction in median total ischemic time from 211 minutes in 2003-2004 to 190 
minutes in 2013-2014, p < 0.001 (74). A nation-wide Polish registry also noted a similar 
decrease in total ischemic time between 2006 and 2013 (268 vs. 230 minutes, p < 0.001) and 
door-to-balloon time (46 vs. 42 minutes, p < 0.001) (75).  
1.7.3 Gender differences in delay time 
Various components of the total ischemic time have been found to be longer for women than 
for men. Based on SWEDEHEART data from 2004 - 2006 (n = 14,380), the median total 
ischemic time was 30 minutes longer for women than for men (3h 30 min vs. 3h, p < 0.001) 
and the median time from first ECG to angiography was five minutes longer for women (76). 
Similar numbers have been reported from the ISACS-TC (International Survey of Acute 
Coronary Syndromes in Translational Countries (n = 6,022) where women had a 30 minute 
longer delay time between symptom onset and hospital presentation, but similar door-to-
needle and door-to-balloon time, compared to men (77). Also, a Danish study found that 
female gender was an independent predictor of patient delay times over two hours (78). 
In an Australian cohort of 735 STEMI patients, female patients had a median door-to-balloon 
time 16 minutes longer than men (88 vs. 72 minutes, p = 0.001) (79). Also, in some 
populations female gender seems to be associated with a lower chance of achieving the target 
of reperfusion within 90 minutes. One study among STEMI patients in New York (n = 245) 
found that female gender had an OR of 0.2 (95% CI 0.1 – 0.6, p = 0.003) of reperfusion 
within 90 minutes compared to men (80). 
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1.8 ACCURACY OF STEMI DIAGNOSIS 
It is important to assess the rapid management of patients with suspected STEMI in 
combination with accuracy of diagnosis. Coronary angiography is an invasive diagnostic 
procedure that comes with both a cost and risk of complications. The rate of false-positive CL 
activations for patients with suspected STEMI seems to be between around ten and up to 50% 
(table 4). Direct comparisons between studies are difficult, as different populations and 
different measures of outcome have been used. A summary of some of the main studies 
aiming to find the rate of false-positive catheterization laboratory activations for suspected 
STEMI is found in table 4. 
Table 4: Studies on the accuracy of diagnosis among patients with suspected STEMI and for whom the 
catheterization laboratory was notified. 
Study n Where was the 
patient when 
diagnosed? 
Who activated the CL? Outcome and rate of 
false-positive activations 
Larson et al., 
JAMA 2007 
(81) 






No culprit lesion and 
negative biomarker: 9% 





56  Field: 41%  
ED: 59% 
Field: ECG interpretation 
computerized. 
ED: ED physicians 
No culprit lesion or 
negative biomarker and 
alternative cause of ST-
elevation on ECG:      
Field-activations: 39%, 
ED-activations: 9% 
Zeymer et al., 
Resuscitation 
2008 (83) 
2,326 Ambulance EMS Physician Discharge diagnosis other 
than STEMI: 10% 
Barge-Caballero 
et al., Rev Esp 
Cardiol 2010 
(84) 
1,662  Out-of-hospital: 
16%              
ED: 84% 
Out-of-hospital: 
Physicians in emergency 
unit 
ED: ED physicians 
No culprit lesion: 7% (95% 
CI: 7-9%) 








ED: ED physicians 
CL cancellation due to 
ECG reinterpretation or 
patient not suitable for 
catheterization:            
EMS: 25%,                
Whole group: 15% 
McCabe et al., 
Arch Intern 
Med 2012 (86) 
411  ED ED Physician 
(Cardiology consultation 
available) 
No culprit artery or, in 
patients without 








Table 4 continued. 
Study n Where was the 
patient when 
diagnosed? 
Who activated the CL? Outcome and rate of false-
positive activations 
Nfor et al., J of 
Emerg Med 
2012 (87) 
489 ED ED physician No culprit lesion: 11% (95% 
CI: 8 – 14%) 
Barnes et al., 
Am J Managed 
Care 2013 (88) 
717 Out-of-hospital: 
33-52% 
EMS or ED Interventional cardiologist 
determined that patient did not 
need emergent transfer: 28%  
Rasmussen et 
al., Heart 2014 
(89) 
919  Ambulance or 
helicopter 
Physician on call in 
hospital 
No STEMI diagnosis (ECG 
and culprit lesion: 16% 




1877 Ambulance Receiving ED physician No PCI or CABG during 
hospital stay: 60% before 2015, 
51% after 2015 
CABG = Coronary Artery Bypass Surgery, CI = Confidence Interval, CL = Catheterization Laboratory, ECG 
= Electrocardiogram, ED = Emergency Department, EMS = Emergency Medical System, PCI = 
Percutaneous Coronary Intervention, STEMI = ST-segment Elevation Myocardial Infarction 
 
1.9 MORBIDITY AND MORTALITY AFTER AN ACUTE MYOCARDIAL 
INFARCTION 
1.9.1 Heart failure 
The development of heart failure after an AMI remains a main concern despite vast medical 
advances over the past decades. Swedish registry data among almost 200,000 hospital 
admissions for AMI between 1996 and 2008 have been used to study the incidence of heart 
failure among AMI patients, and a decline from 46% to 28% has been observed (91). In the 
same study, only around 30% of AMI patients had an LVEF ≥ 50% in 2008. The incidence of 
heart failure after AMI has also been studied using the Danish National Patient Registry. 
Among around 79,000 patients recorded between 2000 – 2009, 21% developed heart failure 
during hospital stay or within a year after the AMI, and patients with heart failure had an 
approximately three-fold increased risk of death within one year (92). 
Women seem to have an increased risk of heart failure after an AMI compared to men. In the 





1.9.2 Sudden Cardiac Death 
Sudden cardiac death is defined as a sudden, unexpected death due to a cardiac cause within 
one hour of symptom onset (94, 95). Approximately 25% of all deaths due to cardiovascular 
diseases are SCD (95). In the setting of myocardial infarction, reduced LVEF has repeatedly 
been shown to be associated with an increased risk of SCD, and the risk of SCD is highest 
early after a myocardial infarction. In the VALIANT (Valsartan In Acute Myocardial 
Infarction Trial) study, 7% of 14,703 patients with an LVEF ≤ 40% experienced SCD or were 
resuscitated after a cardiac arrest during a follow-up period of two years (96). In the trial, the 
median time to event was 180 days and 19% of all events occurred within the first month. 
The risk was highest for those patients who had LVEF ≤ 30%, figure 4 (96). 
Figure 4: Rate of sudden cardiac death or cardiac arrest vs. time after AMI, by groups of ejection 
fraction. Reproduced with permission from Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, 
Velazquez E, Ertl G, et al. Sudden death in patients with myocardial infarction and left ventricular 
dysfunction, heart failure, or both. The New England journal of medicine. 2005;352(25):2581-8. 
Copyright Massachusetts Medical Society. 
1.10 THE IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) 
1.10.1 The evolution of the ICD 
The first ICD was implanted at the Johns Hopkins Hospital in Maryland, USA, by Dr. 
Mirowsky and his team in 1980 (97). The device consisted of an electrode placed in the vena 
cava superior near the right atrium and a patch sutured on to the cardiac apex. Both electrodes 
were then connected to a titanium-encased pulse generator placed in the abdomen. While the 
original ICDs occupied a volume of 145 mL and weighed 250 g, modern ICD devices are in 
the 40 mL range and weigh around 60-70 grams.  
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1.10.2 ICD in secondary prevention 
For patients who have experienced malignant ventricular arrhythmias, the first major trial to 
demonstrate the benefit of an ICD over pharmacological antiarrhythmic therapy was the 
AVID (Antiarrhythmic Versus Implantable Defibrillator) trial (98). In AVID, 1,013 patients 
with ventricular fibrillation or sustained ventricular tachycardia were randomized to receive 
either an ICD or antiarrhythmic medication. The study showed a significant relative risk 
reduction in all-cause mortality of approximately 30% favoring ICD treatment, and the study 
was therefore terminated early. Two other, smaller trials, CIDS (Canadian Implantable 
Defibrillator Study) and CASH (Cardiac Arrest Study Hamburg), showed similar results but 
did not reach statistical significance (table 5). It was argued that, since the AVID was 
terminated early the benefits of ICD treatment might be overestimated. The three studies have 
later been pooled in a meta-analysis, comparing ICD treatment to amiodarone (99). The 
results of the meta-analysis were consistent with the separate studies and found a HR of 0.72 
(95% CI 0.60 – 0.87), p < 0.001 for all-cause mortality and HR 0.5 (0.37 – 0.57), p  < 0.0001 
for death caused by arrhythmia.  
Table 5: Summary of three major studies on the use of implantable defibrillators as secondary prevention 
Study n Inclusion criteria Study groups Relative Risk 
Reduction  
AVID, 1997 (98) 1,013 Near-fatal VF, sustained VT 
with syncope or sustained VT 






31%, p < 0.02 
CIDS, 2000 (100) 659 Documented VF, cardiac 
arrest requiring defibrillation, 
sustained VT with syncope, 
sustained VT > 150 
beats/minutes with LVEF ≤ 
35% and symptoms, syncope 
with evidence of VT 
ICD vs. amiodarone 20%, p = 0.142 
CASH, 2000 
(101) 
288 Resuscitation from cardiac 
arrest, not within 72 from an 
acute myocardial infarction, 
electrolyte disturbances, 
cardiac surgery or pro-
arrhythmic drugs 
ICD vs. amiodarone 
vs. metoprolol 
23%, p = 0.081 
AVID = Antiarrhythmic Versus Implantable Defibrillator, CASH = Cardiac Arrest Study Hamburg, CIDS = 
Canadian Implantable Defibrillator Study, ICD = Implantable Cardioverter Defibrillator, LVEF = Left 
Ventricular Ejection Fraction, VF = Ventricular Fibrillation, VT = Ventricular Tachycardia 
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1.10.3 ICD in primary prevention 
Several clinical trials have demonstrated the benefit of ICD treatment to patients with 
ischemic heart disease and reduced LVEF (102-106), table 6. The relative risk reduction of 
all-cause mortality is approximately 30 – 50% by ICD treatment. The MADIT (Multicenter 
Automatic Defibrillator Implantation Trial) was the first major trial for the primary 
prevention of SCD by ICD. Patients with prior myocardial infarction, LVEF ≤ 35%, non-
sustained ventricular tachycardia and positive electrophysiological provocation were 
randomized to receive either an ICD or pharmacological antiarrhythmic treatment (mainly 
amiodarone). During an average follow-up period of 27 months, the risk of death by any 
cause was significantly lower in the ICD group, HR 0.46 (p = 0.009). Later, the MADIT II 
and the SCD-HeFT (Sudden Cardiac Death – Heart Failure Trial) also confirmed the benefit 
of ICD in patients with patients with prior myocardial infarction and LVEF ≤ 30% and ≤ 35% 
respectively but without the need of electrophysiological studies (104, 105).  
For patients with AMI, the timing of ICD implantation is of great importance. All patients 
included in the MADIT I and II studies had experienced an AMI prior to enrollment in the 
studies. In the first MADIT study, more than six months had passed between the AMI and 
enrollment for over 75% of the study population, and in the MADIT II study the same was 
true for over 87% of the participants. The DINAMIT (Defibrillator IN Acute Myocardial 
Infarction Trial) and IRIS (Immediate Risk-stratification Improves Survival) trials were both 
large randomized controlled trials studying the effect of ICDs implanted early after a 
myocardial infarction. In the DINAMIT study patients were enrolled within 5 – 31 days after 
an AMI and in the IRIS within 4 – 40 days. Both trials failed to show any benefit in all cause 
mortality (table 6).  
Current international guidelines therefore recommend that the decision of ICD implantation 
be delayed until 6-12 weeks after the AMI, after re-assessment of LVEF is performed (15, 
95). According to the ESC guidelines for the management of STEMI patients, ICD treatment 
is recommended to patients with symptomatic heart failure and who are expected to live for at 
least one year with good functional status, if the LVEF is ≤ 35% despite optimal medical 
treatment for at least three months and if at least six weeks have passed since the AMI (15). 
This is stated as a class I level A recommendation, and it is based mainly on evidence from 
the MADIT II and SCD-HeFT trials. As seen in figure 4, the risk of SCD is highest during 
the early phase after an AMI, but, as seen in the DINAMIT and IRIS trials, implantation of an 
ICD within a month from the AMI does not reduce all-cause mortality for patients with 
reduced LVEF. Other parameters than LVEF are therefore of high interest to find in order to 
improve the prognosis for these patients, and to identify at an earlier stage what patients 




Table 6: Summary of major randomized controlled trials on the use of implantable cardioverter 
defibrillators as primary prevention.  
Study n Inclusion criteria Study groups HR (95% CI), for 
all cause mortality 
MADIT, 1996 
(102) 
196 AMI > 3 weeks prior, LVEF ≤ 




0.46 (0.26 – 0.82) 
MUSTT, 1999 
(103) 
704 CAD, LVEF ≤ 40%, NSVT, 
positive EP-study 
Antiarrhythmic 
drugs ± ICD vs. 
no antiarrhythmic 
drugs 
0.45 (0.32 – 0.63) 1 
MADIT II, 2002 
(104) 









NYHA II-III, LVEF ≤ 35% ICD vs. 
amiodarone vs. 
conventional 





NYHA III-IV, LVEF ≤ 35%, 




0.64 (0.48 – 0.86) 3 
DINAMIT, 2004 
(107) 
674 AMI within 6 – 40 days, 
LVEF ≤ 35%, depressed heart 
rate variation or 80 beats/min 
ICD vs. 
conventional 
1.08 (0.76 – 1.55) 
IRIS, 2009 (108) 898 AMI within 31 days, LVEF ≤ 
40% and heart rate > 90 




1.04 (0.81 – 1.35)  
1 Defibrillator vs. no antiarrhythmic drugs  
2 Patients with ischemic cardiomyopathy  
3 Defibrillator vs. conventional group 
AMI = Acute Myocardial Infarction, CAD = Coronary Artery Disease, CI = Confidence Interval, COMPANION 
= Comparison of Medical therapy, Pacing and Defibrillation in Heart Failure, CRT-D/P = Cardiac 
Resynchronization Therapy – Defibrillator/Pacemaker, DINAMIT = Defibrillator IN Acute Myocardial 
Infarction Trial, EP = Electrophysiological, HR = Hazard Ratio, ICD = Implantable Cardioverter Defibrillator, 
IRIS = Immediate Risk-stratification Improves survival, LVEF = Ejection Fraction, MADIT = Multicenter 
Automatic Defibrillator Implantation Trial, MUSTT = Multicenter Unsustained Tachycardia Trial, NSVT = 
Non-Sustained Ventricular Tachycardia, NYHA = New York Heart Association, SCD-HeFT = Sudden Cardiac 





The overall goal of this thesis was to investigate the use of simple diagnostic and clinically 
available measurements on ECG and echocardiography that could improve the prognosis for 
patients with acute myocardial infarction. With fast and correct management of patients with 
AMI, the risk of heart failure could be reduced. And if, despite all efforts, heart failure does 
occur, with faster identification of ICD candidates, the risk of death might be reduced. More 
specifically, the following aims were set: 
 
STUDY I 
To study the rate of false-positive catheterization laboratory activations based on pre-hospital 
ECGs, and to study the delay time intervals for patients with suspected STEMI. 
 
STUDY II 
To study the adherence to the target of acquiring a pre-hospital ECG within ten minutes from 




Among patients with a reduced left ventricular ejection fraction after an acute myocardial 
infarction: to study if simple measurements on stress echocardiography could predict 
improvement of ejection fraction over time.  
 
STUDY IV 
For the early identification of ICD candidates: to study the predictive value of ECG findings 




3 MATERIAL AND METHODS 
3.1 STUDIES I AND II 
3.1.1 The chain of care for patients with suspected STEMI 
EMS personnel first assessed patients who had contacted EMS and for whom an ambulance 
had been dispatched. The investigating hospital was based in Stockholm, Sweden, and served 
a catchment area of approximately 0.5 million inhabitants. Approximately 70 ambulances, 
staffed by one paramedic and one specialist nurse, circulated the area. Pre-hospital ECGs 
were acquired at the discretion of EMS staff for patients with chest pain, but also with other 
symptoms such as syncope or palpitations. The pre-hospital ECG was acquired by the use of 
a portable device (MobiMed, Ortivus, Sweden) and the ECG was transmitted digitally and 
wirelessly to the investigating hospital. At the investigating hospital, each ECG was reviewed 
by a cardiologist or cardiology resident who contacted the ambulance by telephone. If the 
symptoms and ECG signs were consistent with STEMI, the cardiologist immediately 
contacted the CL and a pre-hospital STEMI alert was initiated.  
3.1.2 Time Definitions, Sources, and Intervals 
Measurements of the delay time intervals for patients with suspected STEMI were analyzed 
in studies I and II. Figure 3 and table 7 summarize the definitions used in the studies. 
Table 7: Time definitions and data sources used in studies I and II. 
 Definition Data acquired from 
Symptom onset 
The time when the patient first experienced 
symptoms consistent with STEMI 
Medical charts 
Emergency call 
The time when the patient contacted emergency 
services 
Ambulance charts 
Arrival of EMS 




The time when the pre-hospital ECG was 
transmitted to the investigating hospital 
Database for pre-hospital 
ECG 
Arrival at the hospital 
The time when the ambulance arrived at the 
hospital 
Ambulance charts 
Arterial Puncture The time of arterial puncture in the CL SWEDEHEART 
CL = Catheterization Laboratory, ECG = Electrocardiogram, EMS = Emergency Medical Services, STEMI = 
ST-segment Elevation Myocardial Infarction, SWEDEHEART = Swedish Web-system for Enhancement and 
Development of Evidence-based care in Heart disease Evaluated According to Recommended Treatment 
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For the time interval analyses, the differences between the various time components were 
used. Due to feedback from reviewers and readers after the publication of study I, the 
terminology was slightly changed in study II. A summary of time interval definitions is found 
in table 8. 
Table 8: Time interval definitions used in studies I and II. 
Study I Study II Definition 
 Patient delay Symptom onset to emergency call 
EMS delay Response time Emergency call to the arrival of EMS 
FMC to ECG ECG time Arrival of EMS to the transmission of a pre-hospital ECG 
ECG to door Transport time Pre-hospital ECG to the arrival at the hospital 
Door to needle Hospital time Arrival at the hospital to arterial puncture 
ECG = electrocardiogram, EMS = Emergency Medical Services, FMC = First Medical Contact 
3.1.3 STEMI diagnosis 
The definition of a true STEMI in studies I and II were based on the entry in 
SWEDEHEART. SWEDEHEART is a level one national quality registry and it includes 
information on patients treated for acute myocardial infarction in Sweden. The coverage is 
high and in 2019, 92% of all patients in Sweden up to 80 years of age with myocardial 
infarction were entered in the registry. At the investigating hospital, the coverage is 98%, and 
data entry is continuously monitored both internally and externally.  
3.1.4 Study populations 
In study I, all patients for whom a pre-hospital ECG was transmitted to the investigating 
hospital during 2013 were eligible for inclusion. Patients with faulty transmissions, or 
transmissions intended for other hospital sites (3%) were excluded. 
In study II, all patients with STEMI at the investigating hospital between 17 December 2010 
and 27 July 2015 were eligible for inclusion. Patients who did not arrive by ambulance, or in 
case a pre-hospital ECG had not been transmitted, or if coronary angiography was either not 
performed or if it was delayed for more than six hours, were excluded.  
3.1.5 Other main variables 
Information on background demographics and clinical presentation was obtained from 
medical charts (Take Care®, CompuGroup Medical, Sweden). The status of whether a pre-
hospital CL activation had been performed or not was recorded from locally stored 
information on all pre-hospital ECGs, and confirmed in the medical charts.  
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3.2 STUDY III 
3.2.1 Study population 
All adult patients, admitted for AMI at two participating hospitals, were eligible for inclusion 
if the clinical echocardiogram early after the AMI revealed an LVEF ≤ 40%. Exclusion 
criteria were limited to short life expectancy (within one year), vast comorbidity or refusal to 
participate in the study. Both participating hospitals, Danderyd Hospital and Sodersjukhuset, 
are large teaching hospitals in the urban Stockholm area. 
3.2.2 Echocardiographic examinations 
Patients were invited to undergo baseline resting echocardiography and a low-dose 
dobutamine stress echocardiography within one week after the AMI, before discharge from 
the hospital. Repeated echocardiography was performed after three months. Standard 
commercially available equipment was used for the recording and storing of the examinations 
as well as for the post-processing analyses; GE Vivid 7 and GE EchoPac (GE Vingmed, 
Norway).  
For the resting examinations, a standard echocardiographic examination was conducted. For 
the low-dose dobutamine stress echocardiography, 2D and tissue Doppler images were 
acquired from the apical 4-chamber, 2-chamber and 3-chamber views. A continuous infusion 
of dobutamine at 5 µg/kg/min was then administered through an intravenous line for three 
minutes, after which time the dose was increased to 10 µg/kg/min. After another three 
minutes, the apical images during low-dose dobutamine infusion were obtained. A contrast 
enhancing agent for left ventricular opacification, SonoVue (Braccho, Italy) was used if more 
than 20% of the endocardial border was poorly visualized.  
LVEF was measured using the Simpson Biplane method. Two members of the research team 
independently reviewed and measured the LVEF. If there was less than a five percentage 
point difference between the observers, an average was recorded. If the difference was greater 
than five percentage points, a third member of the team was consulted and a consensus was 
reached. Inter and intra observer analyses were performed. 
Mitral annular plane systolic excursion (MAPSE) and peak systolic velocity (PSV) were 
measured from the apical tissue Doppler images (figure 5). For MAPSE, an average of the 4-
chamber and 2-chamber views was used. For PSV, the average was based on all six basal 
segments from the three standard apical views. The use of MAPSE using tissue Doppler, 
instead of the conventional M-mode analysis, was beneficial as for most points the same 
region of interest could reveal information on both MAPSE and PSV. MAPSE measured by 






Figure 5: In the tissue Doppler images, a region of interest was placed in each of the segments 
surrounding the mitral annulus. Mitral annular plane systolic excursion (MAPSE, left panel) and peak 
systolic velocity (PSV, right panel) were measured. Printed by courtesy of Elif Günyeli. 
3.2.3 Main outcome and other variables 
The main outcome variable was LVEF ≤ 35% at the three-month follow-up visit. Information 
on background demographics and clinical status was collected during study inclusion and at 
the three-month visit.  
3.3 STUDY IV 
3.3.1 Study population 
The study population in study IV was the same as that of study III, with the exception that all 
nine patients from Sodersjukhuset were excluded. The rationale for excluding those patients 
was that the discharge ECG was not always obtainable through the electronic medical chart 
system, and also due to the small number of patients.  
3.3.2 ECG analysis 
Discharge ECGs were obtained through clinical practice, but such ECGs were not always 
available. If no discharge ECG was found in the medical charts, the ECG closest to one week 
after the AMI was used. ECGs were analyzed for rhythm, heart rate, PQ-interval, QRS-
interval, the presence of bundle branch blocks or hemiblocks, ventricular pacing, persistent 
ST-segment elevations, and pathologic Q-waves or R-wave progression. For the three last 
mentioned variables, the definitions stated in table 3 were used, and these findings were only 
studied in patients who did not have intra-ventricular conduction abnormalities (bundle 
branch blocks, hemiblocks or ventricular pacing). 
3.3.3 Main outcome and other variables 
The main outcome in study IV was the dichotomous variable of ICD status. For the 
secondary outcome, medical charts were reviewed to see if the participant had died during the 
long-term follow up. If so, the date and cause of death was recorded from the death certificate 
or through review of the medical chart. Information on whether a life-threatening arrhythmia 




Continuous variables were analyzed for normal distribution by visual inspection of the 
histograms and by the Shapiro Wilk’s test. Normally distributed continuous variables were 
described by mean and standard deviation and were compared by the independent or 
dependent t test where appropriate. Categorical variables were presented as numbers and 
percentages and compared using the chi-squared test, unless the number in any cell was less 
than six in which case Fisher’s exact test was used.  
In study I, quantile regression was used to compare medians of the time intervals, and in 
study II the Wilcoxon Rank-Sum test was used. Quantile regression was also used in study II 
for the multiple variable regression analysis of the time from first medical contact to ECG. 
Quantile regression is a regression tool that does not require the assumptions necessary in 
linear regression models. It allows for comparison of any quantile of interest, and also allows 
for adjusting for other covariates (110). 
In study III, receiver operating characteristics curves (ROC) were graphed and the area under 
the curves (AUC)s were analyzed and compared using the DeLong method (111). The ROC 
AUC is equivalent to the C-statistic. Cut-off values were set to reach the maximal area under 
the curve, and the sensitivity, specificity, positive and negative predictive values were 
presented (figure 6). 
  
Figure 6: An example of a receiver operating characteristics (ROC) curve where the sensitivity is plotted 
on the Y-axis and (1 – specificity) on the X-axis. A continuous variable with a 50-50 chance of predicting 
an outcome would render a line such as the dotted blue line. The area under the curve (AUC) is illustrated 
by the brown lines. The sensitivity (a/(a+c)), specificity (d/(b+d)), positive predictive value (a/(a+b)) and 
negative predictive value (d/(c+d)) can then be established. 
In study IV, the cumulative probabilities of the outcomes were graphed using Kaplan Meier 
curves and differences between groups were compared using the Log-Rank test. Hazard 
ratios were provided by the use of univariable and multivariable Cox regression analyses.  
For all statistical analyses a two-tailed p value ≤ 0.05 was considered significant. All analyses 
were performed using Stata/SE 14.2 (Statacorp LLC, USA). 
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3.5 ETHICAL CONSIDERATIONS 
All studies were in accordance with the Declaration of Helsinki (112). For studies I and II, 
permission was requested from the regional ethics committee, that ascertained that the studies 
did not require formal permission (DNR 2014/294-31). For studies III and IV, permission 
was granted (DNR 2010/882-31/2) and (DNR 2020-04690) and formal written consent was 
obtained from each study participant. 
For all studies, the medical charts of study participants were reviewed which could 
compromise personal integrity. In order to protect the integrity of study participants, several 
precautions were taken. All members of the study team were medical personnel accustomed 
to reviewing confidential information and to the laws of patient confidentiality. All data that 
was collected on paper was stored in a locked room in the research unit, as was the study key 
uniting study identification numbers to personal identification numbers. All digital 
information was stored on secure servers and no personal identification numbers were 
recorded in the digital databases. All results were presented on group level without the 
possibility of identifying individual study participants. 
For studies I and II, no further interventions, examinations or follow-up visits were done 
other than those included in standard medical care.  
For study III, echocardiographic examinations, including a low-dose dobutamine stress 
echocardiogram, were performed and follow-up visits requested. Echocardiographic 
examinations are conducted with the patient lying down and a probe pressed against the 
subject’s chest. This may cause a slight discomfort for patients, especially in the early post-
AMI setting. Patients may also experience a slight discomfort upon administration of 
dobutamine, which may cause palpitations, hypotension and a sensation of stress. In study III, 
the dobutamine infusion was administered at a low concentration with a slow and gradual 
increase, and this is generally well tolerated by patients. Also, the stress part of the test was 
quick, usually less than ten minutes. During the examination an intravenous line had to be 
present, which can be slightly painful and comes with a small risk of infections or 
thrombophlebitis. All patients in study III however, were already admitted to the hospital for 
AMI and already had an intravenous line inserted. The additional risk of complications 
regarding this was therefore considered very low. 
For both studies III and IV, the three month follow-up visit might be seen as a burden to the 
study participants, having to travel back to the hospital for study visits. This should also be 
seen in perspective as all the study participants had an at least moderately reduced LVEF and 
had experienced an AMI. These patients would have been invited to follow-up visits 
regardless of inclusion in the study. Study participation did therefore not add extra visits 
beyond what was already implemented in clinical practice.  
For the long-term follow-up in study IV, no further visits were necessary and all of the long-




4.1 BASELINE CHARACTERISTICS 
Background demographic information on the study populations in studies I – IV is 
summarized in table 9. All studies involved patients with AMI or for whom STEMI was 
highly suspected. In general, patients were around 70 years old and 65 - 77% of them were 
male. Around 20% had diabetes and almost 50% had a previous diagnosis of hypertension. 
Background characteristics were rather similar in all four studies, with the exception for 
smoking status, which was numerically higher in study I and likely due to the fact that 
previous smoking was included in the smoking definition used in that study.  
Table 9: Baseline characteristics of the study populations in studies I – IV. All values presented as 
numbers (percentages) if not otherwise specified. 









(n = 539) 
Patients admitted 
for AMI with 
LVEF ≤ 40% 
(n = 96) 
Patients admitted 
for AMI with 
LVEF ≤ 40% 
(n = 87) 
Age, years, median 
[IQR] 68 [60 - 75] 67 [59 - 76] 71 [62 - 77] 71 [62 - 78] 
Gender, male 75 (65) 385 (71) 73 (76) 66 (77) 
Smoking 63 (55) 136 (25) 29 (30) 26 (30) 
Diabetes Mellitus 21 (18) 104 (19) 19 (20) 18 (21) 
Hypertension 54 (47) 263 (49) 46 (48) 42 (48) 
Prior myocardial 
infarction 13 (11) 87 (16) 13 (14) 13 (15) 
Prior PCI 10 (9) 66 (12) 11 (12) 1 10 (11) 1 
Prior CABG 3 (3) - - - 
Previous heart failure - - 15 (16) 15 (17) 
Atrial fibrillation - - 13 (14) 13 (15) 
1 Patients with previous revascularization, either PCI or CABG 
AMI = Acute Myocardial Infarction, CABG = Coronary Artery Bypass Graft, CL = Catheterization 
Laboratory, IQR = Inter Quartile Range, LVEF = Left Ventricular Ejection Fraction, PCI = Percutaneous 




4.2 STUDY I 
4.2.1 Accuracy in STEMI diagnosis 
During the study period, and after exclusion of test ECGs or incorrectly transmitted pre-
hospital ECGs, 4,298 patients were included in the study. A flow chart of the study patients, 
pre-hospital CL activations and final diagnosis of STEMI is found in figure 7. Among the 
included patients, there were 115 (3%) pre-hospital CL activations based on pre-hospital 
information regarding symptoms and ECG. Background characteristics are found in table 9. 
STEMI-diagnosis was confirmed in 97 (84%) of these patients, yielding a rate of false-
positive CL activations of 16% (95% CI 10 – 23%). 
Among the remaining 4,183 patients, STEMI was found in 42 (1%) patients. One third of 
these patients had been directly admitted to the coronary care unit (CCU), indicating a high 
index of suspicion and also allowing for quick assessment and, if necessary, quick access to 
the CL. However, 28 patients were directed to the emergency department (ED). Among them, 
nine patients had ST-segment elevations on the pre-hospital ECG (six with inferior location, 
two with anterior location and one with lateral location).  
Pre-hospital ECG 
n = 4,298 
Pre-hospital CL activation 
n = 115 
No pre-hospital CL activation 
n = 4,183 
STEMI 
n = 97 
STEMI 
n = 42 
Coronary Care Unit 
n = 14 
ED 
n = 28 
No ST-elevation 
n = 19 
ST-elevations 
n = 9 
Not STEMI 
n = 18 
Not STEMI 
n = 4,141 
 
Figure 7: Flow chart of study the cohort in study I, including information on pre-hospital CL activations 
and final diagnosis of STEMI. CL = Catheterization Laboratory, ED = Emergency Department, STEMI = 
ST-segment Elevation Myocardial Infarction 
4.2.2 Delay time analyses 
For the 115 patients with pre-hospital ECGs, a detailed analysis of the various delay time 
intervals was performed (figure 8). The median time from emergency call to arterial puncture 
was 76 minutes [IQR 65 - 90] and from ambulance arrival to arterial puncture 45 minutes 
[IQR 35 - 54]. There were no significant differences between true STEMI patients and 
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patients with other diagnoses. For patients presenting during office hours, defined as non-
holiday weekdays between 8 a.m. and 4 p.m., the time between arrival at the hospital and 
arterial puncture was significantly shorter, median 16 vs. 26 minutes (p = 0.001). This led to a 
significantly longer delay time between emergency call and arterial puncture for patients 
arriving during on-call hours; 80 vs. 67 minutes, p = 0.003. 
There was a difference in time from the arrival of the ambulance to the transmission of pre-
hospital ECG between women and men. The median time for women was 20 minutes vs. 13 
minutes for men (p < 0.001). Despite this, there was no significant difference in total time 
from emergency call to arterial puncture between men and women. 
 
Figure 8: Delay time intervals for 115 patients with a pre-hospital catheterization laboratory activation. 
EMS = Emergency Medical Services, FMC = First Medical Contact (time that ambulance arrived at 
patient location), Office hours = Non-holiday weekdays 8 a.m. – 4 p.m., On-call hours = all other times, 
STEMI = ST-segment elevation myocardial infarction. Scandinavian Cardiovascular Journal, 52:2, 74-79. 
Reprinted with permission from Taylor & Francis Group. 
The time target of acquiring a pre-hospital ECG within ten minutes of ambulance arrival was 
met for 16%. Arrival of the ambulance to arterial puncture within 60 minutes was reached for 
83%, and within 90 minutes for 98% of the patients. 
4.3 STUDY II 
4.3.1 Patient selection 
During the study period, 916 STEMI cases were identified at the investigating hospital 
through the SWEDEHEART registry. After exclusion of STEMI-patients who did not arrive 
by ambulance, or for whom a pre-hospital ECG was not transmitted, or who either did not 
undergo coronary angiography or if the angiography was delayed more than six hours after 
arrival at the hospital, 539 patients remained. A flow chart describing the patient selection is 




Figure 9: Flow chart describing patient selection in study II. ECG = Electrocardiogram, STEMI = ST-
segment Elevation Myocardial Infarction. SWEDEHEART = Swedish Web-system for Enhancement and 
Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies. 
International Journal of Cardiology 26 (2020), 100458. Reprinted by permission from Elsevier. 
4.3.2 Pre-hospital ECG within ten minutes and delay time analyses 
The target of obtaining a pre-hospital ECG within ten minutes of ambulance arrival was met 
for 22% of the cohort; 29% of the men vs. 14% of the women (p = 0.001). Time from 
emergency call to arterial puncture within 90 minutes was reached for 81% of the men and 
82% of the women (p = 0.557), and time from pre-hospital ECG to arterial puncture within 
90 minutes was achieved for 88% of the men and 89% of the women (p = 0.697).  
Time from symptom onset to emergency call was significantly longer for women, 61 vs. 45 
minutes (p = 0.031). Also, the median time from ambulance arrival to ECG was three 
minutes longer for women than for men (median 17 vs. 14 minutes, p < 0.001) (figure 10). 
After adjusting for age, smoking, LVEF and hypertension, a time difference of two minutes 
remained (p = 0.018). There were no other significant differences in the other delay time 
intervals, or in the total time from emergency call to arterial puncture, between men and 
women. 
 
Figure 10: Delay time intervals for 539 patients with STEMI, arriving by ambulance and for whom a pre-




4.4 STUDY III 
4.4.1 Study population 
In study III, 96 patients admitted for AMI at either of the two participating hospitals, and who 
had an LVEF ≤ 40% were included. Baseline characteristics are found in table 9. There were 
80 patients who underwent both the low-dose dobutamine stress echocardiography and the 
three-month follow-up resting echocardiography.  
4.4.2 Echocardiographic parameters  
Resting and low-dose dobutamine stress echocardiographic examinations were performed 4 
[IQR 3-6] days after the acute myocardial infarction. Median time to repeat echocardiogram 
at three months was 92 days [IQR 90 – 98]. 
Patients who met the primary outcome of LVEF ≤ 35% three months after the myocardial 
infarction had significantly lower LVEF, MAPSE and PSV both during resting 
echocardiography and low-dose dobutamine stress echocardiography (table 10). A contractile 
reserve, defined as an absolute increase in LVEF of ≥ 5 percentage units (113), was found 
during low-dose dobutamine stress echo for 50% of the patients without LVEF recovery and 
77% of the patients with LVEF > 35% at three months (p = 0.012).  
Table 10: LVEF, MAPSE and PSV during resting and low-dose dobutamine echocardiography, by 
groups of patients meeting the ICD-criteria of LVEF ≤ 35% at three months or not. All data presented as 
mean ± standard deviation if not otherwise specified. Data from study III (Open Heart 2019;6:e001053).  
 LVEF ≤ 35% at three 
months  
(n = 32) 
LVEF > 35% at three 
months  
(n = 48) 
p 
LVEF rest, %, median 
[IQR] 28 [24 – 32] 35 [33 – 39] < 0.001 
LVEF low-dose 
dobutamine, % 33 ± 10 44 ± 10 < 0.001 
MAPSE rest, mm 6 ± 1 8 ± 2 0.003 
MAPSE low-dose 
dobutamine, mm 7 ± 1 9 ± 2 0.005 
PSV rest, cm/s 3.4 ± 0.8 4.1 ± 1.0 0.002 
PSV low-dose 
dobutamine, cm/s 4.6 ± 1.1 5.4 ± 1.8 0.042 
ICD = Implantable Cardioverter Defibrillator, IQR = Interquartile Range, LVEF = Left Ventricular Ejection 




4.4.3 The diagnostic ability of resting and low-dose dobutamine stress 
echocardiography before discharge 
The echocardiographic parameters LVEF, MAPSE and PSV, during resting and low-dose 
dobutamine stress echocardiography before discharge from the hospital, were graphed against 
the outcome LVEF > 35% at three months in ROC curves (figure 11). The greatest AUC was 
found for resting LVEF, with an AUC of 85% (95% CI 74 – 94). None of the other variables 
yielded a higher AUC, including after stratifying for atrial fibrillation, myocardial infarction 
prior to the index infarction in the study, CABG or STEMI/non-STEMI. 
 
Figure 11: Receiver Operating Characteristic curves on the discriminatory ability of resting and low-dose 
dobutamine stress echocardiography in determining LVEF > 35% at three months. AUC = Area Under 
the Curve, LVEF = Left Ventricular Ejection Fraction, MAPSE = Mitral Annular Plane Systolic 
Excursion, ROC = Receiver Operating Characteristics. Open Heart 2019;6:e001053. Reprinted by 
permission from BMJ Publishing Group Ltd. 
4.4.4 Performance of binary classifications 
The ROC curves were inspected and cut-off values selected. Sensitivity, specificity, positive 
and negative predictive values were calculated and summarized in table 11. All studied 
variables resulted in fairly high sensitivities around 90-95%, but at the same time fairly low 











Table 11: Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value of different 
echocardiographic measurements in the detection of LVEF ≤ 35% at three months. Data from study III 
(Open Heart 2019;6:e001053).  
 







LVEF rest ≤ 35% 94 40 51 90 
LVEF low-dose 
dobutamine ≤ 45% 91 56 58 90 
MAPSE rest ≤ 8 mm 94 44 54 91 
MAPSE low-
dose dobutamine ≤ 9 mm 93 45 55 90 
PSV rest ≤ 5 cm/s 97 13 43 86 
PSV low-dose 
dobutamine ≤ 6 cm/s 90 31 48 81 
LVEF = Left Ventricular Ejection Fraction, MAPSE = Mitral Annular Plane Systolic Excursion, PSV = Peak 
Systolic Velocity 
 
4.5 STUDY IV 
4.5.1 Study population and ICD implantation 
There were 87 patients included in study IV, who were followed on average for 6.1 ± 2.1 
years. Background characteristics are found in table 9. During the follow-up time, 26 (30%) 
patients received an ICD. The median time from AMI to ICD was 127 [IQR 21 – 170] days.  
There were no statistically significant ECG differences in terms of rhythm, ventricular 
frequency, PQ-interval, QRS-interval, or the presence of intra-ventricular conduction 
abnormalities between those who received an ICD and those who did not (table 12). Patients 
who did not receive an ICD were, however, more often female (70% vs. 92%, p = 0.027), and 
were more likely to have diabetes (29% vs. 4 %, p = 0.010) and had less often a myocardial 





Table 12: General ECG findings in study cohort and differences between patients who received an ICD 
vs. those who did not. All values presented as numbers (percentages) if not otherwise specified. 
 All 
(n = 87) 
Received ICD 
(n = 26) 
No ICD 
(n = 61) 
p 
 
Sinus rhythm 78 (90) 25 (96) 53 (87) 0.269 
Atrial fibrillation 7 (8) 0 7 (11) 0.098 
Ventricular frequency, beats/min, 
median [IQR]  
76 [67 - 90] 72 [61 - 79] 79 [71 - 90] 0.054 
PQ interval, ms, median [IQR]  170 [150 - 190] 170 [150 - 190] 170 [150 - 190] 0.925 
QRS interval, ms, median [IQR]  90 [90, 110] 95  [90, 130] 90 [85, 100] 0.191 
Intra-ventricular conduction 
abnormalities (LBBB, RBBB, 
pacemaker, LAH, LPH) 
19 (22) 8 (31) 11 (18) 0.188 
ICD = Implantable Cardioverter Defibrillator, IQR = Interquartile Range, LAH = Left Anterior Hemiblock, 
LBBB = Left Bundle Branch Block, LPH = Left Posterior Hemiblock, ms = milliseconds, RBBB = Right 
Bundle Branch Block.  
4.5.2 Prediction of need for an ICD by ECG 
Apart from the 19 patients with intra-ventricular conduction abnormalities, the discharge 
ECGs for the remaining 68 patients were examined for the presence of pathologic Q-waves, 
pathologic R-wave progression and remaining ST-segment elevations. Patients who received 
an ICD more often had a pathologic R-wave progression than those who did not (83% vs. 
46%, p = 0.011). Pathologic R-wave progressions and also lateral Q-waves were both 
predictors of an increased risk for ICD implantation in the univariable analysis (table 13). 
After adjusting for gender, previous myocardial infarction and the diagnosis of STEMI, the 
increased risk remained. For those with a pathologic R-wave progression, the adjusted HR 
was 4.0 (95% CI 1.1 – 14.3, p = 0.033) for the identification of ICD patients. This risk 
remained when LVEF was also included in the model (HR 4.0, 95% CI 1.2 – 14.9, p = 
0.035). 
The sensitivity for either pathologic R-wave progression or pathologic Q-waves for the 
detection of ICD patients was 83%. In the total cohort, there were fifteen (17%) patients who 
did not have pathologic Q-waves, pathologic R-wave progression or intra-ventricular 
conduction abnormalities. None of them received an ICD during follow-up, and none of them 
suffered from malignant arrhythmias during the study period. Four of the patients died during 




Table 13: Cox regression analysis for ICD-implantation, n = 68. Multivariable analysis adjusted for 
gender, previous myocardial infarction prior to the index infarction, and STEMI diagnosis. 
 Univariable Multivariable 
 HR (95% CI) p HR (95% CI) p 
Presence of pathologic 
Q-waves 
2.70 (0.78-9.33) 0.117 2.03 (0.52-7.89) 0.307 
   Anterior location 0.88 (0.34-2.26) 0.783 0.79 (0.29-2.16) 0.645 
   Lateral location 5.54 (1.56-19.65) 0.008 4.79 (1.28-17.87) 0.020 
   Inferior location 1.61 (0.57-4.53) 0.365 1.14 (0.40-3.21) 0.809 
Pathologic R-wave 
progression 
4.98 (1.44-17.26) 0.011 4.00 (1.12-14.32) 0.033 
Remaining ST-
elevation 
2.43 (0.91-6.50) 0.076 2.37 (0.79-7.13) 0.125 
 
4.5.3 Cumulative ICD or CRT-D treatment 
Survival curves of cumulative ICD or CRT-D treatment were graphed using Kaplan-Meier 
curves (figure 12). Patients with pathologic R-wave progression were significantly more 
likely to receive an ICD than patients who did not (Log Rank p = 0.005). Combining the 
ECG parameters, none of the patients who did not have intra-ventricular conduction 
abnormalities, pathologic Q-waves or a pathologic R-wave progression received an ICD 
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Figure 12: Kaplan-Meier graphs on cumulative ICD or CRT-D treatment. Graphs A-C include the 68 
patients included in the ECG analysis, while graph D includes the full cohort of 87 patients. Patients 
grouped by: A) pathologic Q waves, B) pathologic R-wave progression, C) remaining ST-segment 
elevations and D) either pathologic Q waves, pathologic R-wave progression or intra-ventricular 
conduction abnormalities. 






















5.1 MAJOR FINDINGS 
In study I, one in six patients with a suspected STEMI based on pre-hospital ECGs was 
discharged with an alternative diagnosis. Measured from the time of arrival of the ambulance, 
the time target of reperfusion therapy within 90 minutes was achieved for almost all patients 
(98%), but the achievement of a pre-hospital ECG within ten minutes was only met for 16% 
of the cohort. The delay time to pre-hospital ECG was significantly longer for women than 
for men. 
In study II, a pre-hospital ECG was obtained within ten minutes for only around one fifth of 
the patients, and the target was more likely to be achieved for men than for women. Almost 
90% reached the target of reperfusion therapy within 90 minutes. Women had a significantly 
longer delay time between symptom onset and emergency call.  
In study III, among patients with an at least moderately reduced LVEF after an AMI, 60% 
recovered their LVEF to ≥ 35% after three months. Patients with LVEF ≤35% at three 
months had a significantly lower left ventricular function at both resting and stress 
echocardiography measured by LVEF, MAPSE and PSV before discharge. Baseline LVEF 
was a good predictor of recovery with a ROC AUC of 85%, and none of the other variables, 
including those measured during stress echocardiography, were better discriminators. 
In study IV, patients with LVEF ≤ 40% after an AMI and who had a pathologic R-wave 
progression on the discharge ECG were four times more likely to receive an ICD compared 
to those with normal R-wave progressions. None of the patients without a pathologic R-wave 
progression, pathologic Q-waves, or intra-ventricular conduction abnormalities, received an 
ICD or suffered from malignant arrhythmias during the follow-up period.  
5.2 STEMI DIAGNOSIS 
5.2.1 Why study the rate of false-positive STEMI diagnoses? 
The benefit of rapid management of STEMI patients is well supported and has been discussed 
in chapters 1.6 and 1.7. Every 30-minute delay is associated with a relative risk of around 
1.08 for one-year mortality (114). Also, every hour of delay is an independent predictor for 
heart failure with a HR of 1.10 (95% CI 1.02 – 1.17) (115). But are there problems associated 
with being too fast?  
In a hypothetical scenario, if the availability of catheterization laboratories and staff were 
unlimited all patients included in study I (n = 4,298) could have been referred directly to 
coronary angiography. Although only 139 of these patients were true STEMI patients, for 
them fifteen minutes could have been saved by not acquiring a pre-hospital ECG. Further, it 
can be speculated that with unlimited access to the catheterization laboratory, another fifteen 
minutes could be saved due to improvement of in-hospital systems, such as having the teams 
ready and working at all hours. In this scenario, it is possible that 30 minutes of ischemic time 
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could be saved. Assuming that the one-year mortality rate at the investigating hospital in 
study I is similar to the one reported by De Luca et al. (5.8%) (114), the hypothetical situation 
would reduce the annual number of deaths from 8.1 patients to 7.4 patients. Also, using data 
from Desta et al. that 28% of the STEMI patients develop heart failure (91) and extrapolating 
data that there is a 10% increase in the risk of heart failure for every additional hour of delay 
(115), this would mean that number of heart failure patients would be reduced from 39 to 37. 
On the other hand, there would be 4,298 – 139 = 4,159 coronary angiograms performed for 
patients unlikely to benefit from them. Although the risk of complications during 
angiographic examinations has decreased vastly over the years, based on published rates of 
complication the experiment of referring all patients with pre-hospital ECGs to the CL would 
cause 103 cases of contrast induced nephropathy, 42 pseudo-aneurysms and 33 deaths 
(complication rates based on those reported by Tavakol et al.) (116). Assuming a cost of 
around 10,000 SEK for each angiogram (personal communication, Dr. Persson, Danderyd 
Hospital), this scenario would also put a ≈ 43 million SEK (≈ 5.1 million USD) financial 
burden on the hospital budget for this single center alone. Also, there would be a need for a 
vast increase in the number of catheterization laboratories, staff, and other resources. It is 
clear that careful patient selection is motivated. 
5.2.2 What is a correct STEMI diagnosis? 
In order to find the true rate of false-positive STEMI diagnoses, a clear definition of a correct 
diagnosis is needed. The definition of a correct STEMI diagnosis is somewhat complicated. 
At the time of diagnosis in the pre-hospital setting, biomarkers are usually not available and 
the diagnosis is based on the evaluation of the clinical scenario and the pre-hospital ECG. In 
many systems, the person initiating the pre-hospital CL activation is not on location in the 
ambulance, but will have to rely on the reports of the clinical status by telephone 
communication with EMS staff. This may affect decision-making, and the rates of false-
positive CL activations may differ depending on whether the patient was evaluated in person 
in the emergency department or by indirect communication. Also, the ECG can be equivocal 
and true ST-segment elevations are not always present in the setting of an occluded coronary 
vessel. Several other ECG configurations have been identified as “STEMI-equivalents” 
(figure 13). 
Even the definition of an occluded coronary is by itself not enough for the diagnosis of 
STEMI. Among the 12,657 patients with STEMI-diagnosis included in the FITT-STEMI trial 
(Feedback Intervention and Treatment Times in ST-elevation Myocardial Infarction), 0.3% of 
the patients had no “coronary arteries narrowed” (117) and in a meta-analysis combining 
eight independent randomized STEMI trials (n = 14,929), 0.2% of the patients were excluded 
due to the fact that they had non-significant obstructions in the infarct related artery (118). In 
both these examples, the percentage of patients without occluded or critically compromised 
coronary arteries was very low. This is likely due to the fact that other diagnoses were offered 
to patients without coronary lesions, thus excluding them from participation in the studies. 
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When looking at a more unselected material, such as in clinical practice, the lack of finding a 
culprit vessel on coronary angiography is significantly higher as was seen in table 4.  
 
 
Figure 13: ECG patterns associated with a high risk of critical coronary artery stenosis or occlusions. 
Asatryan el al, Electrocardiographic Diagnosis of Life-Threatening STEMI Equivalents – When every 
minute counts. JACC:Case Reports.2019;1(4):666-8. Reprinted by the permission of the CC BY-NC-ND 
LICENSE http://creativecommons.org/licenses/by-nc-nd/4.0. 
Further more, a significant proportion of patients diagnosed with non-STEMI have occluded 
arteries. In one meta-analysis including 40,777 patients, 25.5 % were found to have an 
occluded coronary artery (119).  
In studies I and II, the definition of a true STEMI was based entirely on what was entered in 
the national quality registry SWEDEHEART. Based on the fourth universal definition of 
myocardial infarctions, in order to establish that a type 1 acute myocardial infarction is 
present, there is a need for both elevated cTn levels and one of either symptoms, ECG 
findings, imaging evidence or identification of a coronary thrombus by angiography (14). 
Only symptoms, possibly information regarding risk factors, and a pre-hospital ECG are 
available in the field setting, thus making a final diagnosis of STEMI impossible at such an 
early stage. The results of the investigations performed later, during hospital admission, such 
as coronary angiography, lab results including cTn, echocardiography and the clinical 
 
42 
scenario will certainly contribute to whether a final diagnosis of STEMI is set or not. This 
was the motivation of using the SWEDEHEART entry as the main outcome variable in study 
I, and inclusion variable in study II.  
5.2.3 The rate of false-positive STEMI 
The rate of false-positive pre-hospital CL activations was 16% for the detection of patients 
with STEMI in study I. The patients who had pre-hospital CL activations but did not receive 
a STEMI diagnosis were diagnosed with unspecific chest pain, non-STEMI, pericarditis, 
angina pectoris, dilated cardiomyopathy, left bundle branch block, cardiac arrest, or 
pancreatitis. The patient who suffered from cardiac arrest could not be resuscitated. No 
autopsy was performed and it is possible that this patient could have been misclassified as not 
having STEMI. For that patient, and the patient with pancreatitis, no angiography was 
performed. It can easily be argued that all of the remaining patients with pre-hospital CL 
activations the angiographies were still beneficial for identifying or ruling out significant 
coronary lesions. Then, if using the somewhat subjective outcome “necessary emergency 
coronary angiography”, the rate of false-positivity in study I would be reduced from 16% to 
1% (that percent being the patient with pancreatitis).  
Taken into consideration all the discussed difficulties in establishing what a true STEMI 
diagnosis really is, especially in the pre-hospital setting, and also the complex nature of 
human biology, the rate of false-positives is unlikely to ever be zero. An analogy can be 
drawn to what surgeons have experienced in appendectomies. Traditionally, surgeons have 
accepted a false-positive rate in performing appendectomies for appendicitis of 
approximately 20%, in order to reduce morbidity that can follow missed diagnoses (120). 
However, between 1996 and 2006, reports from one hospital found a decrease from 24% to 
3% (p < 0.001) due to advances in pre-operative imaging (ultrasound and computerized 
tomography) (121). Can something similar be done in pre-hospital STEMI care? The use of 
portable troponin assays that can be used in the out-of-hospital setting has shown promising 
results. Stopyra et al. found that obtaining a point of care troponin level in the pre-hospital 
setting was feasible for 83% of the attempts (122). The authors report a sensitivity of 27% 
and a specificity of 92%. In a Danish cohort, Sorensen et al. report that a pre-hospital 
troponin level was feasible to obtain in 97% of the attempts and that the values could identify 
30% of patients diagnosed with AMI (123). The use of pre-hospital cTn in a broader clinical 
perspective remains to be seen. 
The rate of false-positive pre-hospital STEMI diagnoses will thus depend highly on the 
definition of population studied, in what time aspect, and how the diagnosis STEMI is 
defined. Nevertheless, the importance of having some type of follow-up regarding this has 
been stressed. In a Swedish setting, the combination of the different registries in 
SWEDEHEART could easily provide continuous monitoring and benchmarking regarding 
this, possibly with a slight modification in the input variables. Based on the findings in study 
I, and the studies presented in table 4, a proposed target of around 15% seems plausible. 
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5.3 TIME COMPONENTS AND GENDER DIFFERENCES 
5.3.1 Patient delay 
In study II there was a difference in median time from symptom onset to emergency call 
between men and women, where women called emergency services about fifteen minutes 
later than men. Larger reports from SWEDEHEART and ISACS-TC, have found differences 
of around 30 minutes (76, 77), and in the Vienna registry, a difference was 19 minutes was 
found (124). It is possible that the slightly lower time difference between the genders reported 
in study II is due to the smaller number of patients or regional differences in behavior in 
when to seek medical care. The clinical significance of patient delay is important and it is 
likely that time to presentation contributes to the increased mortality among women seen in 
many studies. In the Vienna registry for example, the increased mortality both during hospital 
stay and during long-term follow-up seen in the univariable regression model, was no longer 
significant when adjusted for clinical covariates and time to presentation (124). Although not 
being the sole factor for prognosis, it is unlikely that a longer delay from symptom onset to 
medical attention would be beneficial in any way.  
A possible cause for the longer patient delay times for women could be due to variations in 
clinical presentation. In a Swedish questionnaire-based study among 532 STEMI admitted to 
the CCU, chest pain was less common among women than among men (74% vs. 93%, p < 
0.001), whereas other symptoms such as nausea (49% vs. 29%, p < 0.001) and shoulder pain 
(33% vs. 15%, p < 0.001) were more frequent (125).  
In studies I and II, the remaining delay time intervals are all less than 30 minutes. The 
symptom delay times reported from Vienna were 109 vs. 91 minutes (124), in 
SWEDEHEART 210 vs. 180 minutes (76), in ISACS-TC 270 vs. 240 minutes (77) and in 
study II 61 vs. 45 minutes for women vs. men. Viewing this in relation to the fact that the rest 
of the delay time between emergency call to arterial puncture was around 80 minutes in study 
II, it is likely that in order to improve the chain of care for patients with STEMI even further, 
efforts should be made to make patients with STEMI seek emergency care sooner.  
5.3.2 Delay in diagnosis 
In both studies I and II, only a low proportion of patients with possible STEMI is diagnosed 
by pre-hospital ECG within ten minutes from EMS arrival. In study I the proportion was 16% 
and in study II 22%. The ESC has issued a class IB recommendation of a target delay of no 
more than ten minutes to obtain an ECG (15). This recommendation is based on two 
references (126, 127). The first study is based on data from the CRUSADE (Can Rapid Risk 
Stratification of Unstable Angina Pectoris Suppress Adverse Outcomes with Early 
Implementation of the American College of Cardiology/American Heart Association 
Guidelines) Quality Improvement Initiative study, and included data from over 63,000 
patients with non-STEMI seeking care in the emergency department. In that study, reported 
by Diercks et al., 35% had an initial ECG taken within ten minutes from arrival at the 
hospital. After adjusting for clinical factors (including age, gender and comorbidities) and 
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hospital factors (including teaching vs. non-teaching facilities and physician specialty) no 
differences were found neither in death nor post-admission myocardial infarction (126). The 
second study motivating the class IB classification is a pooled analysis of ten independent 
registries in the United States, reported by Rokos et al. The study included 2,712 patients who 
were diagnosed with STEMI by the use of pre-hospital ECGs. Among the 2,053 patients who 
underwent primary PCI, the authors found a door-to-balloon time ≤ 90 minutes for 86% and 
an ECG-to-balloon time ≤ 90 minutes for 68% of the patients (127). The measurement of 
time from ambulance arrival to pre-hospital ECG was not the aim of the article although it is 
briefly mentioned in the discussion.  
While the impact of the use of pre-hospital ECGs in STEMI care is well supported, it thus 
seems as the impact of the acquisition of such an ECG within ten minutes is much less 
supported. A small report by Studnek et al. among 165 STEMI patients with a pre-hospital 
STEMI alert, the median time from EMS arrival to pre-hospital ECG was 5.1 minutes. 
Adjusting for age, gender and race, the authors report that patients with pre-hospital ECG 
within eight minutes were more likely to reach time to reperfusion ≤ 90 minutes, OR 3.4 
(95% CI 1.2-9.3) (128).  
Whatever the optimal time from ambulance arrival to pre-hospital ECG is, it is likely that 
every minute counts even in this phase of the total ischemic time. STEMI care monitoring 
system or registries, that focus mainly on monitoring times from the STEMI diagnosis 
(including pre-hospital ECG based) might thus miss an important part of the delay time. If the 
acquisition of a pre-hospital ECG is much delayed, e.g. in the ambulance five minutes prior 
to arrival in the hospital, the time from STEMI-diagnosis to reperfusion will be short. If the 
pre-hospital ECG is taken in the patient’s home, prior to loading the patient in the ambulance, 
the performance of the hospital will look “worse” if the time is measured from the time of the 
ECG. It is likely that the measurement of the whole time chain, from the onset of symptoms 
to reperfusion therapy, as well as the discussed time intervals in between, will provide a less 
biased view of the total ischemic time.  
5.4 WHO NEEDS AN ICD AFTER A MYOCARDIAL INFARCTION? 
5.4.1 The optimal outcome in studies aiming to predict future ICD 
candidates 
The aim of studies III and IV was to identify predictors, before discharge from the hospital 
and while the patient was still admitted for an AMI, for the eligibility of ICD therapy 
according to guideline recommendations. In study III the best echocardiographic predictor of 
finding patients with LVEF ≤ 35% after three months was resting LVEF with a ROC AUC of 
85%. In study IV patients with a pathologic R-wave progression had a four-fold increased 
risk of obtaining an ICD during the study period. There are strengths and limitations in the 
choice of outcomes used in these studies. In the MADIT II and SCD-HeFT studies, both 
demonstrating reductions in mortality by ICD treatment in post-AMI patients, the inclusion 
criteria included LVEF ≤ 30% (MADIT II) and LVEF ≤ 35% (SCD-HeFT) (104, 105). Later, 
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it became clear in the DINAMIT and IRIS studies, that LVEF measured early after an AMI is 
not a sufficient criterion to select patients for ICD treatment (107, 108). Nevertheless, despite 
all the limitations that exist regarding LVEF, this parameter has consistently been shown 
across studies to be a strong and robust prognostic marker. In both the DINAMIT and IRIS 
trials, the risk of arrhythmia related death was reduced by the early implantation of ICDs, but 
the risk of non-cardiac deaths was increased.  
An ICD is unlikely to prevent any other types of deaths than those that are arrhythmia related, 
and hence the identification of malignant arrhythmias would probably be the best outcome. 
Studies III and IV were not designed to use SCD or malignant arrhythmias as primary 
outcome and the number of patients in the studies that experienced such arrhythmias was 
relatively low (9% in study III, 14% in study IV). In one study, based on the patients with 
heart failure after AMI who were included in the VALIANT study but who died, autopsy 
reports were available for 398 patients. Among them, 26% were classified as have died due to 
SCD, and among them 51% were presumed to be due to arrhythmic causes and 42% due to 
fatal myocardial infarctions (remaining causes of SCD were heart failure, overdose, 
pulmonary embolism or stroke) (129). It is however likely that at least a proportion of the 
patients who died due to recurrent myocardial infarctions also had malignant arrhythmias. In 
a hypothetical calculation, if 100 patients with heart failure die after an AMI, and 26% of 
them are SCD, and say 60% of those with SCD are arrhythmia related, then sixteen patients 
could possibly be saved by an ICD. The absolute risk reduction would hence be around 16% 
and the number needed to treat 6.4.  
The use of risk scores has been suggested and examples include the Duke Sudden Cardiac 
Death Risk Score (130) and the risk score proposed by Docherty et al. (131). The ROC AUC 
of the Duke Score was 0.75 (internal validation) and 0.64 (external validation), and for the 
Docherty score 0.72. Both these scores include LVEF as well as other clinical characteristics, 
but their usefulness in clinical practice for the identification of ICD candidates after an AMI 
remains to be seen. 
In study IV, the main outcome used in the study was ICD implantation. The decision of 
placing a primary preventive ICD is generally not done until after re-evaluation of LVEF 6-
12 weeks after the AMI. Current guidelines recommend that ICDs be offered to patients with 
symptomatic heart failure with LVEF ≤35% measured after at least six weeks after the AMI 
despite optimal medical therapy, and who are expected to live for at least one year with good 
functional status (15). The decision of treatment with an ICD does not come without bias. 
One retrospective study previously published by the study group found inadequate follow-up 
in 32% of the patients, mostly due to the fact that no follow-up echocardiography was 
ordered (132). Similar findings have been reported from another study group in Israel where 
29% did not have repeat echocardiography (133). This highlights the need for identification 
of ICD candidates before hospital discharge. In the study setting in studies III and IV, this 
was perhaps less likely to happen due to the fact that the patient was enrolled in a study, but it 
may affect generalizability as follow-up in clinical practice is usually not as rigorous as in a 
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research study. Nevertheless, even in the study setting 17% of enrolled patients who 
underwent the first low-dose dobutamine stress echocardiographic examination did not do the 
three month examination, mostly due to vast comorbidity.  
5.4.2 The role of stress echocardiography 
In study III, none of the studied stress echocardiography measurements were superior to 
baseline LVEF in the prediction of patients meeting the ICD criteria of LVEF ≤ 35% after 
three months. Still, baseline LVEF, was a strong discriminator with a ROC AUC of 85% 
(numerically higher than the risk scores mentioned in chapter 5.4.1). As mentioned in the 
introduction, stress echocardiography is known to be able to identify myocardial viability and 
contractile reserve. In hibernating segments of the myocardium with severely reduced 
perfusion the response to dobutamine can be either absent or below visual detection. This 
may lead to a number of false-negatives. The sensitivity of the dobutamine stress 
echocardiography to detect viability with functional recovery is around 75-80% (134). 
Resting LVEF after myocardial infarction has been shown to be a predictor of recovery at 
three months to LVEF ≥ 35%, and patients with resting LVEF 31-35% are almost seven 
times more likely to recover than patients with LVEF ≤ 25% (135). 
In study III, only LVEF, MAPSE and PSV were analyzed during baseline and low-dose 
dobutamine stress echocardiography. It is possible that these measurements are too global in 
a sense that more regional abnormalities are not accounted for. In a study by Swinburn et al., 
a Wall Motion Score during low-dose dobutamine stress echocardiography provided 
incremental information over resting data in terms of predicting death and non-fatal AMI 
(136). This was not measured in study III as the aim was to find less time-consuming 
methods that were easier to obtain in clinical practice. More advanced parameters such as 
strain or strain rate, have been shown to be predictors of both total infarct size and death after 
an acute myocardial infarction (137). This is true for both patients with reduced LVEF and 
normal LVEF post-infarction (138, 139). However, measurement of global strain by speckle 
tracking is dependent on good image quality, which is not always feasible in the clinical 
setting. This was also the reason for usage of more easily quantifiable parameters such as 
MAPSE and PSV in study III.  
5.4.3 The role of discharge ECG 
In study IV, the main finding was that patients with a pathologic R-wave progression after an 
AMI had a four-fold increased risk of treatment with an ICD during the follow-up period. 
Patients without a pathologic R-wave progression, pathologic Q-waves, or intra-ventricular 
conduction abnormalities were identified as a low-risk group and in study IV no such patients 
received an ICD.  
For patients with AMI, normal ECGs have been associated with an improved prognosis. In 
one observational study (n = 391,208), patients with AMI and with a normal initial ECG had 
an approximately 40% lower risk of in-hospital mortality, compared to those patients with 
ST-segment elevations, ST-segment depressions or LBBB (140). Viewing discharge ECGs 
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for AMI patients, both remaining ST-segment depressions and remaining Q-waves have been 
associated with both an increased risk of re-infarction and death within six months (141). 
However, having an increased risk for all-cause mortality is not synonymous to having a 
possible benefit from ICD implantation. For example, although QRS duration has been 
associated with increased mortality (142) it did not predict ventricular arrhythmias in patients 
with ICDs (143). 
In study IV, although there was a trend towards statistical significance, patients with 
pathologic Q-waves did not have an increased risk of ICD implantation. A possible 
explanation could simply be due to lack of power, although the number of cases in the R-
wave calculation was similar to the number in the Q-wave calculation. Another possible 
explanation could be that the current definition of pathologic Q-waves was not robust 
enough. The classic definition of Q-waves (duration ≥ 40 ms and/or depth ≥25% of R) has 
been shown to be better correlated with infarct size measured by cardiac magnetic resonance 
than the newer classification of Q-waves used in study IV (44).  
5.5 LIMITATIONS 
Studies I and II were single center observational studies which may affect generalizability. 
The investigating hospital is one of the largest cardiology clinics in Sweden with a high 
number of various types of cardiology patients, including STEMI patients, each year. 
According to SWEDEHEART data, the performance of the investigating hospital in STEMI 
care is high. Also, due to its location in an urban setting, the times of transportation are likely 
to be shorter than in more rural parts of Sweden and the world. Despite the vast experience of 
the hospital, the rate false-positive pre-hospital STEMI diagnosis of about 16%. It is possible 
that this rate is higher in sites with less experience, and the importance is perhaps not the 
number itself but fact that it should be monitored.  
The fact that the time target of the acquisition of a pre-hospital ECG within ten minutes was 
only met for around 20% of the study cohort, even for patients with STEMI, is concerning. A 
majority of patients for whom a pre-hospital ECG is obtained do not have STEMI. These 
patients are likely to have more unclear symptoms, and it is possible that the time to pre-
hospital ECG is even longer for that group. In study II, only patients with true STEMI were 
included in the study, and we can therefore not make inference on ambulance performance in 
an unselected material. 
The time of ambulance arrival, both at the patient location and at the hospital, was logged by 
ambulance staff and later obtained by ambulance charts. The logging of correct times could 
possibly be affected by patient status, e.g. if the patient was unstable the log time could have 
been delayed. It was not possible to retrospectively check if the correct time was entered by 
EMS and it is not possible to rule out some degree of non-random misclassification. 
However, as all patients in the main analysis in study I had pre-hospital CL activations, and 
all patients in study II had STEMI, it is likely that such misclassifications would rather 
provide longer delay times than the “truth”, and if anything might under-estimate the 
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proportion of patients receiving reperfusion within 60 or 90 minutes. Time of ambulance call 
and pre-hospital ECG was recorded by automatic clock and those times are therefore more 
robust.  
The definition of STEMI used studies I and II was based on the entry in the national quality 
registry SWEDEHEART. This was discussed in chapter 5.2.2. The coverage of 
SWEDEHEART is highest for patients under the age of 80 and might not be complete for 
older patients. In study I, medical charts for all patients in the main analysis were scrutinized 
and there were no additional STEMI patients found. Also, the investigating hospital has a 
high coverage especially for patients with STEMI, regardless of age. The fact that cases 
would unintentionally be excluded is unlikely.  
Most of the patients in study III, and all of the patients included in study IV, were also 
included from a single center. Patients in all four studies had relatively similar baseline 
characteristics. However, invasive and medical treatment for patients with AMI in sites with 
less experience or lower patient volumes may be different. For instance, after an AMI at the 
investigating hospital, close follow-up with dedicated nurses and outpatient treatment 
follows. According to the study protocol, patients in studies III and IV were all invited for a 
repeat echocardiography three months after the myocardial infarction. Although 17% did not 
do the three-month echocardiogram, the percentage of failure to repeat echocardiography is 
higher in clinical settings.  
LVEF was the main predictor variable and also the main outcome variable in study III. 
Although seemingly an easily obtained echocardiographic measurement the measurement of 
LVEF can be subjective and incorrectly quantified. In order to reduce this, each LVEF 
measurement was done by at least two independent members of the study team and intra and 
inter observer correlations were reported. Also, measurements of MAPSE and PSV, which 
generally show less variability, were reported. It is likely that the use of contrast enhancing 















The rate of false-positive catheterization laboratory activations, based on pre-hospital ECGs 
and information, is low and similar to rates reported by studies on in-hospital diagnoses. 
Also, the goal of achieving reperfusion within 90 minutes is obtained for most patients. 
Female patients have longer delay times from symptom onset to emergency call. Also, for all 
patients but especially for female patients, the goal of obtaining a pre-hospital ECG within 
ten minutes is reached for only a fraction of patients with true or possible STEMI. 
For patients who are diagnosed with AMI and who have a reduced LVEF during admission, a 
majority of patients will recover the LVEF to ≥ 35% at three months. Although lower LVEF 
at baseline predicted non-recovery, measurement of LVEF, MAPSE and PSV on low-dose 
dobutamine stress echocardiography did not add further information. However, patients with 
pathologic R-wave progression before discharge from the hospital were four times more 
likely to receive an ICD during follow up. Patients who did not have pathologic R-wave 
progression, or Q-waves or intra-ventricular conduction abnormalities were unlikely to 

































7 CLINICAL IMPLICATIONS 
 
In order to reduce morbidity and mortality for patients with STEMI, management of such 
patients needs to be fast and correct. The importance of studying time intervals can give 
important clues on where the time bandits are and can thus provide information on where 
efforts of improvement should be focused. In study I, the rate of false-positive pre-hospital 
STEMI alerts was relatively low. However, this was a single center study and even if the 
same definition of true STEMI is used, it is likely that the number will vary both over time 
and also between different sites. Using the quality registry SWEDEHEART and information 
from SCAAR (the Swedish Coronary Angiography and Angioplasty Registry, a part of 
SWEDEHEART), the rate of false-positive pre-hospital catheterization laboratories could 
easily be monitored for all sites treating patients with STEMI in Sweden. Benchmarking and 
comparisons between sites could be done and time trends assessed. Also, by obtaining large 
data regarding the rate of false-positives, it is likely that the optimal target regarding this 
could be established and possibly the care for patients with STEMI improved.  
 
Studies I and II both address the fact that among patients with suspected or true STEMI, a 
pre-hospital ECG within ten minutes from ambulance arrival is obtained for only around 
20%. The time target of ten minutes, established by international guidelines, does not have a 
strong evidence-based background and despite the fact that most patients did not have a pre-
hospital ECG within ten minutes, the over-all time target of reperfusion therapy within 90 
minutes was met for almost all patients. Time intervals could also efficiently be monitored by 
the use of SWEDEHEART. Only measuring time from ECG to reperfusion therapy can 
easily lead to false conclusions. Easily obtainable time measurements, such as time of 
emergency call, time of ambulance arrival, time of pre-hospital ECG, time of arterial 
puncture and time of wire passage are all parts of the ischemic time that is affected by EMS 
and hospital performance, and should be monitored. The fact that women seem to wait longer 
after symptom onset could possibly be addressed by information campaigns, but should then 
also be monitored continuously in order to see if the efforts are effective.  
 
Study III revealed that the measurement of LVEF, MAPSE and PSV on low-dose 
dobutamine stress echocardiography did not add further information on which patients 
improve their LVEF to more than 35% after three months. It is possible that more advanced 
echocardiographic measurements on low-dose dobutamine stress echocardiography could be 
used to discriminate better, but study III does not support the use of routine stress-
echocardiography after an AMI.  
 
For patients with a reduced LVEF after an AMI, the discharge ECG contains prognostic 
information and should be obtained for all patients. Patients with either a pathologic R-wave 
progression, pathologic Q-waves or intra-ventricular conduction abnormalities have a higher 
risk of needing an ICD in the future than patients who do not. More comprehensive studies 
will have to demonstrate if early implantation of an ICD is beneficial for this group or not.  
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8 FUTURE PERSPECTIVES 
In all four studies in this thesis the sample sizes were relatively small and the studies were in 
general limited to one investigation site. It is possible that, in the future, most of the findings 
from all four studies in fact could be obtained from the national quality registry 
SWEDEHEART. For studies I and II, only small adjustments to the input variables in the 
sub-registries Riks-HIA and SCAAR need to be made in order for continuous monitoring of 
false-positive rates, time intervals and gender differences. Most sites in Sweden report very 
short delay times, usually measured as time from the ECG that confirmed ST-segment 
elevations to arterial puncture. This time interval will miss all the false-negative pre-hospital 
ECG interpretations as the pre-hospital ECG is then, in some scenarios, never even taken into 
consideration when measuring hospital performance. A proposed way of addressing this 
would be to enter time of emergency call, time of pre-hospital ECG and information on 
whether such an ECG was used to activate a pre-hospital STEMI alert. This would be a better 
way to monitor the performance of the pre-hospital part of the time chain. 
The search of patients suitable for early implantation of ICDs continues. Studies addressing 
this face the challenge that the rate of sudden cardiac death or resuscitation from malignant 
ventricular arrhythmias is relatively low and large studies with long follow-up need to be 
conducted. Big data from national registries could facilitate patient inclusion, but are not 
always as detailed studies III and IV. For example detailed discharge ECG information is 
lacking. Merging of the level I national cardiac arrest registry and SWEDEHEART and 
analyzing obtainable background information and in-hospital information, could possibly 
identify a risk score to identify patients with the highest risk of SCD, similar to the CHA2DS2 
VASc risk score for the risk of thromboembolism in patients with atrial fibrillation. After 
internal and external validation, further studies would then have to demonstrate the benefit of 





















9 SVENSK SAMMANFATTNING 
 
Introduktion 
Trots stora framsteg inom hjärtinfarktvården är hjärtinfarkt en av de vanligaste dödsorsakerna 
i världen. För patienter med hjärtinfarkt och ST-höjningar på EKG (STEMI) har snabb 
handläggning visat sig vara associerad med en bättre prognos både avseende död och 
följdsjukdomar såsom hjärtsvikt. Flera åtgärder inom den prehospitala vårdkedjan kan 
påskynda handläggningen för dessa patienter. Exempelvis kan patienter, med hjälp av trådlös 
överföring av prehospitala EKG från ambulans till sjukhus, hänvisas direkt till 
kranskärlsröntgen. Värdefull tid kan då sparas. Det är dock viktigt att ha en korrekt diagnos 
tidigt, eftersom patienten hänvisas direkt till en utredning med invasiva metoder utan att 
remitterande läkare har haft möjlighet att direkt träffa patienten. Att ställa en korrekt diagnos 
under dessa förutsättningar kan vara utmanande för den remitterande läkaren. Internationella 
riktlinjer har satt upp mål för hur lång tid olika aspekter inom vårdkedjan för STEMI-
patienter högst bör ta. Könsskillnader i måluppfyllelse avseende dessa tidsaspekter, samt 
måluppfyllelsen att ta ett prehospitalt EKG inom tio minuter från ambulansens ankomst är 
inte noga studerade. 
För patienter som överlever en hjärtinfarkt kvarstår en risk för bestående eller övergående 
hjärtsvikt. Graden av hjärtsvikt kan kvantifieras med hjälp av ekokardiografi. Det är visat att 
patienter med en försämrad hjärtfunktion, definierat som låg ejektionsfraktion, har en 
försämrad prognos jämfört patienter med normal ejektionsfraktion. För de patienter som har 
en kvarstående låg ejektionsfraktion trots optimal medicinsk behandling tre månader efter en 
hjärtinfarkt, kan en implanterbar defibrillator (ICD) förbättra överlevnaden. Vinsten med 
ICD-behandling ses dock inte förrän efter flera månader efter en hjärtinfarkt. Detta 
kompliceras av det faktum att risken för plötslig hjärtdöd är som högst under den första tiden 
efter en hjärtinfarkt. Därför skulle det vara fördelaktigt att finna prediktorer för de patienter 




Det övergripande målet med avhandlingen var att finna enkla och kliniskt relevanta mått på 
EKG och ekokardiografi som kan förbättra prognosen för patienter med akut hjärtinfarkt. 
Mer specifikt var huvudmålen: 
Studie I: Att studera andelen falskt-positiva STEMI-patienter där diagnosen har ställts baserat 
på prehospital information. 
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Studie II: Att studera könsskillnader avseende tidsintervaller i handläggningstid för STEMI-
patienter och att studera hur ofta målet att erhålla ett prehospitalt EKG inom tio minuter från 
ambulansens ankomst nås. 
Studie III: Att studera om stressekokardiografi med lågdos dobutamin kan särskilja de 
patienter som återhämtar sin vänsterkammarfunktion efter en hjärtinfarkt, från de patienter 
som inte gör det. 
Studie IV: Att undersöka om utskrivnings-EKG i samband med ett vårdtillfälle för 




I studier I och II utgjorde alla konsekutiva patienter, för vilka ett prehospitalt EKG hade sänts 
till det undersökande sjukhuset, studiebasen. I studie I var insamlingstiden januari – 
december 2013 och i studie II december 2010 till juli 2015. I studie I erhölls information om 
huruvida ett prehospitalt STEMI-larm hade utfärdats via medicinska journaler. För båda 
studier inhämtades information om STEMI-diagnos från kvalitetsregistret SWEDEHEART. 
Tidsintervaller beräknades med hjälp av tidsangivelser från patientjournal, ambulansjournal, 
databas för prehospitala EKG och SWEDEHEART. 
I studier III och IV inkluderades vuxna patienter som vårdades inneliggande för hjärtinfarkt 
och hade en ejektionsfraktion högst 40 %. Kort förväntad överlevnad och ovilja att delta i 
studien utgjorde exklusionskriterier. I studie III utfördes en stressekokardiografisk 
undersökning med lågdos dobutamin under vårdtiden för hjärtinfarkten. I studie IV 
studerades det EKG som togs innan patienten skrevs ut från sjukhuset.  
 
Resultat 
I studie I var det 115 patienter som remitterades direkt från ambulans till kranskärlsröntgen 
för misstänkt STEMI. Av dessa var det 16 % (95 % CI 10-23%) som skrevs ut med annan 
diagnos än STEMI. Tidsmålet för reperfusionsbehandling inom 90 minuter uppnåddes för 
nästan alla patienter (98 %), men målet med prehospitalt EKG inom tio minuter från 
ambulansens ankomst nåddes endast för 16 % av kohorten. Tiden till prehospitalt EKG var 
signifikant längre för kvinnor än för män; median 20 minuter jämfört med 13 minuter (p < 
0.001). 
I studie II inkluderades 539 patienter med STEMI för vilka ett prehospitalt EKG hade sänts 
till det undersökande sjukhuset. För 22 % av kohorten hade det prehospitala EKGt tagits 
inom tio minuter. Målet nåddes i högre grad för män än för kvinnor (29 % jämfört med 14 %, 
p = 0.001). Trots detta, nåddes målet med reperfusionsbehandling inom 90 minuter för 88 % 
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av alla patienter och det förelåg ingen könsskillnad avseende detta. Kvinnor hade dock en 
signifikant längre tid mellan symtomdebut och larmsamtal än män.  
I studie III inkluderades 96 patienter med ejektionsfraktion ≤ 40 % som vårdades 
inneliggande för hjärtinfarkt. Av dem genomgick 80 patienter både stressekokardiografi med 
lågdos dobutamin under vårdtiden samt ett uppföljande tremånaders eko. Av dessa 80 
patienter, var det 32 (40 %) patienter som hade en ejektionsfraktion ≤ 35 % efter tre månader. 
Dessa patienter hade signifikant lägre värden avseende ejektionsfraktion och longitudinell 
funktion i samband med hjärtinfarkten. Ejektionsfraktion i vila hade en ROC AUC på 85 % 
(95 % CI 74-94%) för detektion av förbättring. Inga av de andra studerade parametrarna, 
varken på vilo-ekokardiografi eller stressekokardiografi med lågdos dobutamin, hade större 
ROC AUC. 
I studie IV studerades utskrivnings-EKG på 87 patienter som ingick i studie III. De som hade 
en nedsatt R-vågsprogression hade en fyra gånger ökad risk att erhålla en ICD under 
uppföljningstiden. Ingen av patienterna som inte hade en nedsatt R-vågsprogression, eller 
patologisk Q-våg, eller intraventrikulära ledningshinder erhöll en ICD under 
uppföljningstiden, och ingen av dem drabbades av livshotande arytmier.  
 
Sammanfattning 
Bland de patienter som remitteras direkt från ambulansen till kranskärlsröntgen för misstänkt 
STEMI, är andelen patienter som skrivs ut med alternativa diagnoser låg och väl jämförbar 
med rapporter baserade på akutmottagningens bedömning. Tidsmässigt finns könsskillnader 
där män generellt har en kortare tid mellan symtomdebut och larmsamtal samt mellan 
ambulansankomst och prehospitalt EKG. Målet att ta ett prehospitalt EKG inom tio minuter 
nås endast för ungefär en femtedel av patienterna och det finns stort utrymme till förbättring 
avseende detta.  
För patienter med hjärtsvikt efter en hjärtinfarkt är ejektionsfraktion en stark prediktor för 
framtida förbättring. Enkla mått med stressekokardiografi med lågdos dobutamin tillförde 
ingen prognostisk information. Patienter med en nedsatt R-vågsprogression i samband med 
en hjärtinfarkt har en signifikant ökad risk att behöva en ICD, medan patienter som varken 
har en nedsatt R-vågsprogression, patologiska Q-vågor eller intraventrikulärt ledningshinder 
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